

IN THE NEBRASKA SUPREME COURT

STATE OF NEBRASKA,

Case No. S-86-946

Appellee,

v.

MICHAEL W. RYAN,

Appellant.

RECEIVED
STATE'S RESPONSE TO
MOTION TO SHOW CAUSE

JAN 09 2012

CLERK
NEBRASKA SUPREME COURT
COURT OF APPEALS

The appellee State of Nebraska responds to the appellant Michael W. Ryan's "Motion to Show Cause", "Supplemental Showing Re: Motion to Show Cause", and "Second Supplemental Motion to Show Cause" (hereafter jointly referred to as "Motion to Show Cause") as follows:

Background

On Nov. 3, 2011, the State of Nebraska filed a "Motion to Set Execution Date", which requested this Court to establish a date certain and issue a death warrant to enforce Ryan's death sentence judgment. Ryan responded by filing a "Motion to Recuse Nebraska's Attorney General's Office, Appoint Independent Counsel, and Stay Proceedings for Issuing a Death Warrant" (hereafter "Motion for Stay and to Recuse"), which latter motion made a variety of method of execution claims concerning the State's acquisition of sodium thiopental, which is one of the drugs for the execution protocol established by state statute and

regulation. On December 21, 2011, this Court denied Ryan's Motion for Stay and to Recuse upon finding that Ryan's motion was "unpersuasive and without merit."

Despite this Court's finding that Ryan's prior Motion for Stay and to Recuse was unpersuasive and without merit, Ryan's Motion to Show Cause again makes method of execution allegations concerning the State's acquisition of sodium thiopental.

Argument

Ryan's Motion to Show Cause makes frivolous, dilatory, and irrelevant allegations concerning the issue of setting an execution date and issuing a death warrant. Ryan does not allege any error in the death penalty judgment which the State seeks to enforce nor does he challenge the constitutionality of § 83-964 (Cum. Supp. 2010), which requires that a sentence of death in the State of Nebraska be enforced by the "intravenous injection of a substance or substances in a quantity sufficient to cause death." Ryan also does not challenge the validity of the Nebraska Department of Correctional Services ("DCS") execution protocol.

State v. Mata, 275 Neb. 1, 69 (2008), required that the State, when seeking enforcement of a valid and final sentence of death, demonstrate that "a constitutionally acceptable method of carry out [a sentence of death] is available." The State's pending Motion to Set Execution Date has so demonstrated. The Motion contains identical allegations to a similar motion filed in *State v. Moore*, S-

95-0485. In *Moore*, this Court previously held that, “Because the State has alleged that Nebraska’s lethal injection statutes are ‘constitutionally acceptable,’ and since statutes are presumed to be constitutional, [citation omitted] we conclude that the State has met its pleading burden under *Mata*.” *State v. Moore* (Order of April 21, 2011, p. 2.)

As previously stated in the State’s Motion to Set Execution Date, DCS has in its custody and control the substances required by the DCS execution protocol to conduct an execution pursuant to § 83-964 *et.seq.* (Cum. Supp. 2010). DCS has verified the identity and efficacy of the sodium thiopental by independent laboratory testing.

Ryan’s Motion to Show Cause challenges the source of the substances which are intended to be employed to carry out Ryan’s death sentence. The source of the substances to be used to carry out a death sentence is irrelevant to assuring the protections of the Eighth Amendment of our federal constitution. *Brewer v. Landrigan*, Supreme Court of the United States, No. 10A416 (Oct. 26, 2010) (vacating order for a stay of execution, which stay was initially granted on ground one of the drugs to be used in the execution was obtained from a foreign source); *Cook v. Brewer*, 637 F.3d 1002,1006-1007 (9th Cir. 2011), *cert.den.* 131 S. Ct. 2465 (2011); *West v. Brewer*, CV-11-1409 (USDC AZ) (Dec. 21, 2011) (no showing of bad faith on the part of the State of Arizona as a result of importing

sodium thiopental for use in enforcing a sentence of death); *Valle v. State*, 70 So. 3d 530 (Fla. 2011).

The DCS execution protocol is consistent with the requirements of the Eighth Amendment of the federal constitution. *Jones v. Hobbs*, 604 F.3d 580 (8th Cir. 2010) (Arkansas lethal injection protocol upheld); *Nooner v. Norris*, 594 F.3d 592, 596 (8th Cir. 2010); *Clemons v. Crawford*, 585 F.3d 1119, 1125 (8th Cir. 2009)(Missouri lethal injection protocol upheld). *Jackson v. Danberg*, 594 F.3d 210, 212 (3rd Cir. 2010); *Emmett v. Johnson*, 532 F.3d 291 (4th Cir. 2008); *Raby v. Livingston*, 600 F.3d 552 (5th Cir. 2010); *Dickens v. Brewer*, 631 F.3d 1139 (9th Cir. 2011); *Cook v. Brewer*, 2011 U.S. App. LEXIS 5212 (9th Cir. 2011) (dismissal for failure to allege a viable claim affirmed); *Cook v. Brewer*, 637 F.3d 1002,1006-1007 (9th Cir. 2011) (dismissal for failure to allege a viable claim on additional allegations affirmed); *Wackerly v. Jones*, 398 Fed. Appx. 360, 363 (10th Cir. 2010) (The order of judgment of the district court denying a stay of execution affirmed.); *Pavatt v. Jones*, 627 F.3d 1336 (10TH Cir. 2010) (stay denied); *Brewer v. Landrigan*, Supreme Court of the United States, No. 10A416 (Oct. 26, 2010) (vacating order granting stay of Arizona execution on ground that one of the drugs to be used in the lethal injection process was obtained from a foreign source); *Beaty v. Brewer*, 2011 U.S. App. LEXIS 11391, 27-28 (9th Cir. Ariz. May 25, 2011) (denying stay of execution when drug switched from sodium thiopental to

pentobarbital on 18 hours' notice; rejecting both 8th Amendment and Due Process claims); *Rivas v. Thaler*, 2011 U.S.App. LEXIS 14471 (5th Cir. 2011) (denying a certificate of appealability on a challenge to Texas' execution protocol); *DeYoung v. Owens*, 2011 U.S. App. LEXIS 15794, 17-18 (11th Cir. 2011) (use of pentobarbital approved); *Powell v. Thomas*, 643 F.3d 1300 (11th Cir. 2011) (Alabama's change from sodium thiopental to pentobarbital did not violate the Eighth Amendment.). *Jackson v. Danberg*, 656 F.3d 157 (3^d Cir. 2011) (pentobarbital substituted for sodium thiopental does not violate the Eighth Amendment.); *Rhoades v. Reinke*, 2011 U.S. App. LEXIS 22929 (9th Cir. Nov. 16, 2011) ("The district court correctly concluded that the SOP 135 protocol, as it will be implemented, is not only substantially similar to the Kentucky protocol as described in *Baze*, but includes more safeguards than the Kentucky protocol. In this light, Rhoades's claim that Idaho's lethal injection protocol violates the Eighth Amendment fails."); *Rivas v. Thaler*, 432 Fed. Appx. 395, 404-405 (5th Cir. 2011) (Certificate of appealability denied on *Baze*-based challenge to Texas lethal injection protocol.); *West v. Brewer*, CV-11-1409 (USDC AZ) (Dec. 21, 2011).

Ryan has made no claims that the method of execution is cruel and unusual punishment or violates the Nebraska or federal constitutions. The appropriate forum for raising method of executions claims of the type alleged by Ryan is a

separate proceeding, pursuant to 42 U.S.C. § 1983, not an attack upon the judgment of conviction in this Court. *State v. Moore*, 272 Neb. 71, 80 (2006):

. . . Moore has not filed this case as a § 1983 action but instead has filed for relief under Nebraska's postconviction statute. As such, Moore has not alleged facts which if proved would render his sentence of death void, and we conclude that in an action under Nebraska's postconviction statute, an issue of constitutional dimension involving a sentence does not constitute grounds for postconviction relief unless it also constitutes grounds for finding the sentence void or voidable.

See also, *State v. Moore*, at 79 (“§ 1983 was the appropriate vehicle for the prisoner to challenge the particular lethal-injection procedure”, citing *Nelson v. Campbell*, 541 U.S. 637, 124 S. Ct. 2117 (2004), as authority). Whether a method of execution is cruel and unusual punishment bears solely on the legality of the execution of the sentence and not on the validity of the sentence itself. *State v. Ellis*, 281 Neb. 571 (2011).

Ryan's declination to seek relief for his method of execution allegations in the appropriate legal forum is further evidence of the dilatory nature of his Motion to Show Cause, which was filed on the heels of this Court's prior order finding that Ryan's Motion to Stay and Recuse was without merit. Ryan's reluctance to file in the appropriate forum is not unexpected, as the courts, including the United States

Supreme Court, have routinely rejected the allegations he makes regarding the importation of the drug. *Brewer v. Landrigan*, Supreme Court of the United States, No. 10A416 (Oct. 26, 2010) (No evidence that drug from foreign source is unsafe. Speculation cannot substitute for evidence to satisfy Eight Amendment standard); *Cook v. Brewer*, 637 F.3d 1002,1006-1007 (9th Cir. 2011), *cert.den.* 131 S. Ct. 2465 (2011); *West v. Brewer*, CV-11-1409 (USDC AZ) (Dec. 21, 2011) (no showing of bad faith on the part of the State of Arizona as a result of importing sodium thiopental for use in enforcing a sentence of death. Court rejects allegations that State was devious and reckless).

Additional Information: State's Good Faith vs. Ryan's Bad Faith

Although Ryan has failed to present a legally valid theory as to why his death sentence should not be enforced, Ryan persists in his attempts to delay enforcement by filing pleadings with sensational, false, and conclusory allegations concerning the irrelevant issue of the process by which DCS came into custody of sodium thiopental.

To demonstrate that the State has acted in good faith and that Ryan's Motion to Show Cause has been made in bad faith, the State submits the following concerning its acquisition of the drug sodium thiopental:


1. Narrative of Events (Attachment 1)
2. Supporting documentation for the Narrative (Attachment 2)

Conclusion

WHEREFORE, the State of Nebraska requests that this Court deny Ryan's Motion to Show Cause and sustain the State's Motion to Set Execution Date.

STATE OF NEBRASKA, Appellee,


BY JON BRUNING, #20351
Attorney General

BY 
James D. Smith, #15476
Assistant Attorney General
Chief of Criminal Appeals
2115 State Capitol
Lincoln, NE 68509-8920
Tel: (402) 471-2682

Attorneys for the Appellee

Certificate of Service

A copy of the foregoing Response to Motion to Show Cause, with attachments, has been served upon the appellant by regular United States mail, postage prepaid, addressed to appellant's attorney of record Gerald L. Soucie, Nebraska Commission on Public Advocacy, 140 N. 8th Street, Suite 270, P.O. Box 98932, Lincoln, NE 68509-8932 on the 9th day of January, 2012.


James D. Smith
Assistant Attorney General

State v. Ryan, No. S-86-946

Narrative of Events

Attachment 1 to State's Response to Motion to Show Cause

Narrative of Events:
Nebraska's Acquisition of the Drug Sodium Thiopental

On November 11, 2010, the Department of Correctional Services (DCS) entered into an agreement with an independent foreign contractor to purchase sodium thiopental, one of the drugs used in the execution protocol. A foreign contractor was necessary because DCS had determined that sodium thiopental was unavailable in the United States. The foreign contractor was Chris Harris of Kayem Pharmaceuticals in India (Kayem).

Over the next year, two separate shipments of sodium thiopental were received by DSC from its foreign contractor, paid for by DCS, and confirmed to be the drug sodium thiopental by separate independent laboratory testing. DCS' current supply of sodium thiopental has cleared federal U.S. Customs & Border Protection (U.S. Customs) and has been authorized to be in the possession of DCS by all of the appropriate federal government authorities.

As DCS prepared to import the first shipment of sodium thiopental, U.S. Customs advised DCS to retain an import broker before the drug would be allowed to enter the United States. DCS then contracted with Phil Patterson, Inc., (Patterson) to act as the State's import broker.

On or about December 14, 2010, the first shipment of sodium thiopental arrived in Omaha and was placed in a bonded warehouse to be released to Patterson after Patterson obtained authorization from Customs and the U.S. Food and Drug Administration (FDA). Patterson contacted Customs and was given information about the documentation needed

for Customs to authorize release of the sodium thiopental. Customs informed Patterson that it needed to complete various U.S. Customs and Food and Drug Administration (FDA) forms. Patterson was not informed by those federal agencies (Customs and FDA) that a form from another federal agency, U.S. Drug Enforcement Agency (DEA) form 236, was also required. Patterson completed the Customs and FDA forms and obtained authorization from Customs and the FDA by early January 2011 for release of the drugs.

On January 7, 2011, the first shipment of sodium thiopental was released by the United States and delivered to DCS. DCS sent vials from the shipment of sodium thiopental to Medtox Laboratories, Inc. for independent laboratory testing to confirm that the drug was, in fact, sodium thiopental. Lab test results from Medtox confirmed that the drug was, in fact, sodium thiopental. After DCS received independent laboratory confirmation, the Attorney General's Office was advised that DCS had the required drugs to perform an execution in accordance with Nebraska's execution protocol.

On January 24, 2011, the Nebraska Attorney General's Office filed a Motion to Lift Stay and Set an Execution Date with the Nebraska Supreme Court in *State v. Carey Dean Moore*. The Court granted the State's motion on April 21, 2011, and set Carey Dean Moore's execution for June 14, 2011.

Moore's attorney sent a letter dated March 28, 2011, to the DEA asking for an investigation of the DCS's acquisition of the first shipment of sodium thiopental. Upon inquiry, Patterson informed DCS that DEA Form 236 should have been completed for the sodium thiopental shipment. Thus, on April 1, 2011, DCS completed DEA Form 236 and

returned it to Patterson for submission to DEA. On April 6, 2011, DCS received a copy of the DEA form 236 that was validated by Customs and submitted to DEA.

After submission of and Customs' validation of DEA form 236, DCS began receiving apparent conflicting information from separate federal DEA offices in Kansas City and Washington, D.C. On April 8, 2011, DEA agent Betty Veney (Veney) of the DEA's Washington, D.C. office contacted DCS to discuss the Form 236 that was submitted and to assist DCS in clarifying information on the form. On April 11, Veney contacted DCS again seeking more information to help process Form 236. On April 12, 2011, Veney contacted DCS and informed DCS that it also needed to submit DEA Form 225 for import registration in order for DCS to import sodium thiopental. Veney advised DCS that not completing Form 225 in advance of importation had happened in the past and was not critical to obtaining importation registration.

Contrasted with the information received by DCS from the DEA's Washington, D.C. office, DCS was contacted on April 12, 2011 by DEA's Kansas City regional office and advised by Kansas City DEA agent Judy Williams (Williams) that there might be paperwork problems because of non-completion of DEA forms. But, Williams told DCS that this matter (the State's non-completion of DEA forms) was not high on her radar, and that the issue could not be resolved the week of April 12. From the time of the release of the shipment of sodium thiopental by Customs on January 7, 2011, until Veney's inquiry on April 8, 2011, no agencies of the United States government had contacted DCS concerning its possession of sodium thiopental.

On April 15, 2011, DCS submitted the completed DEA Form 225 to the DEA. On April 26, 2011, Williams contacted DCS and left a message indicating DEA will set a time to come to Lincoln to pick up the sodium thiopental. This was the first time DCS received any clear contact from a federal official indicating any intention to retrieve the sodium thiopental that was in possession of DCS after having already cleared Customs. Thus, DCS contacted the Nebraska Attorney General's Office about the message from Williams.

On April 27, 2011, Nebraska Chief Deputy Attorney General David Cookson (Cookson) became involved to clarify the federal government's position concerning the sodium thiopental that was in the possession of DCS. Cookson decided to contact federal officials at a sufficient high level of authority. Thus, Cookson contacted Monty Wilkinson (Wilkinson), the Deputy Chief of Staff to the United States Attorney General. Wilkinson referred Cookson to Deborah Johnston (Johnston), the Associate Deputy Attorney General for the United States Department of Justice (USDOJ). An agreement was reached whereby the State agreed to delay filing a lawsuit for a Declaratory Judgment action against DEA and the DEA agreed to not seize the State's sodium thiopental pending a meeting to reach a resolution of the matter of the DCS having possession of its first shipment of sodium thiopental.

On May 6, 2011, a meeting was held in Washington, D.C. among Cookson on behalf of the State of Nebraska, Johnston on behalf of the U.S. DOJ, Wendy Coggin, General Counsel for DEA, Joseph Rannazzisi (Rannazzisi), DEA Deputy Chief of Operations, Office of Diversion Control, and Robert Gleason, DEA Office of Counsel.

During the May 6th meeting, the State and USDOJ agreed that the DEA's only issue was the need for an import license to import sodium thiopental. Thus, the USDOJ and the State agreed to proceed on two parallel tracks to resolve the import license issue. The first track involved the State's current supply of sodium thiopental received by the first shipment. The State and USDOJ/DEA agreed that they would continue to work on DCS obtaining an importer license, which DCS had applied for on May 2, 2011, and that the DEA would expedite the 4-6 week license process so as to allow DCS to use the sodium thiopental received in the first shipment from India. The second track was that USDOJ/DEA agreed to help expedite the State's acquisition of a second batch of sodium thiopental from an existing licensed importer before the scheduled execution of Carey Dean Moore. Significantly, it was further agreed that the State would retain possession of the sodium thiopental during this parallel process until either an agreement was reached on DCS's use of its sodium thiopental or an alternative supply was obtained by DCS.

Counsel for Moore and Ryan has made numerous public records requests to DCS and the Nebraska Attorney General's Office. However, those requests did not request any documents concerning the direct communication between the Nebraska Attorney General's Office and USDOJ/DEA concerning the DCS import license issue.

In furtherance of the first track and after multiple conversations between DCS and DEA, on May 25, 2011, Williams (DEA) conducted an inspection of the DCS facilities. This inspection was the final step for DCS to obtain an importer's license. After the inspection and on the same day, DCS was granted its importer's license. The issuance of

DCS' importer's license, effectively resolved in the State's opinion the issue of DCS's possession of the sodium thiopental received in the first shipment.

In furtherance of the second track, Rannazzisi (DEA) provided the Nebraska Department of Justice with a list of importers approved for obtaining a new supply of sodium thiopental. Elliot Safdie (Safdie) of Caligor Rx was contacted on May 18, 2011 as a possible importer of the sodium thiopental selected by DCS from the DEA approved list. Harris Pharma LLP (Harris), the same Harris formerly of Kayem, had previously agreed to provide a new supply of sodium thiopental to DCS as an independent contractor for DCS. After discussions with Harris, Safdie informed DCS that he could possibly have a second batch of sodium thiopental by June 10, 2011. However, on May 23, 2011, Safdie informed DCS that due to quality control procedures, the sodium thiopental would not come into his possession until a later date. This effectively ended the second resolution track with regard to Moore's scheduled execution. However, by this time the State was two days from obtaining its import license (see above, on May 25th), which was consistent with its understanding that DCS could pursue the option of using its existing supply sodium thiopental obtained in the first shipment. A conference call with USDOJ/DEA was held on May 23, 2011 to update them on the current status of the joint efforts. When the State obtained its importer's license on May 25, 2011, Safdie's services were no longer required.

At the same time the two-track resolution process between the State and USDOJ/DEA was occurring, Moore filed an Emergency Motion for Stay of Execution with the Court on May 17, 2011. The State entered its objection on May 18, 2011, with

Moore filing a Reply two days later. The Court ordered a Stay of Execution on May 25, 2011, which was the same day the State had obtained its importer's license. The State's use of its first shipment of sodium thiopental for Carey Dean Moore's execution on June 14th was now moot because of the stay of execution. USDOJ/DEA extended its agreement not to ask DCS for its supply of sodium thiopental pending DCS's acquisition of a new supply of sodium thiopental.

DCS continued its previous efforts to obtain a new supply of sodium thiopental from Harris. On August 25, 2011, DCS received an invoice from Harris for a delivery of a second shipment of sodium thiopental. DCS sent a check for payment of the invoice on September 14, 2011. Harris then placed a purchase order with the Indian company NAARI on September 15, 2011 to obtain the second shipment sodium thiopental. On September 29, 2011, Aaditya Sinha (Sinha), a representative of NAARI, emailed Harris to confirm that Harris would receive 500 vials of sodium thiopental and that payment of approximately 20,000 rupees (Rs) should be made to Jagsonpal Pharmaceuticals Ltd. (Jagsonpal) and sent to Attn: Aaditya Sinha, Jagsonpal Pharmaceuticals Ltd.. Harris then received the sodium thiopental from NAARI, through Jagsonpal, along with a Certificate of Analysis (COA) confirming the drug as sodium thiopental. *On October 1, 2011, Harris submitted a check in the amount of 20,475 Rs to Jagsonpal as payment for the second shipment of sodium thiopental.* On that same date, Sinha by email confirmed that NAARI/Jagsonpal had received Harris' check for the sodium thiopental. Also, on that same date, Harris notified DCS that (1) Harris was in possession of the sodium thiopental, (2) Harris had a valid Certificate Of Analysis, and (3) Harris was in the

process of shipping both to DCS. *On October 20, 2011, the check to Jagsonpal for 20,475 Rs was cashed and debited to Harris' bank account with Axis Bank, thus confirming payment had been made to NAARI, as they had instructed, for the sodium thiopental shipped to Harris.*

The second shipment of sodium thiopental cleared customs in India on October 19, 2011 and arrived in the United States via Fed Ex on October 20, 2011. On October 24, 2011, the DEA, FDA and Customs released the sodium thiopental to DCS. *DCS submitted sample vials of the second shipment of sodium thiopental to Medtox Laboratories, Inc. for testing. On October 27, 2011, the State received a lab report from Medtox verifying that the drug in the vials was, in fact, sodium thiopental.*



On November 3, 2011, the Nebraska Attorney General's Office filed a Motion to Set Execution Date in *State v. Michael Ryan*.

State v. Ryan, No. S-86-946

Supporting Documents for Narrative of Events

Attachment 2 to State's Response to Motion to Show Cause

**Sodium Thiopental: Delivery and clearance of second
shipment by federal authorities (October 2011)**

U. S. Department of Justice / Drug Enforcement Administration		OMB APPROVAL No. 1117 - 0009
CONTROLLED SUBSTANCES IMPORT / EXPORT DECLARATION		See reverse for Privacy Act
(Read instructions on reverse before completing)		
1. CHECK ONE	<input checked="" type="checkbox"/> IMPORT DECLARATION Nonnarcotic Substances in Schedules III, IV, V <input type="checkbox"/> EXPORT DECLARATION Nonnarcotic Substances in Schedules III, and IV and all substances in Schedule V	U.S. CUSTOMS CERTIFICATION Date of Departure / Arrival: 10/24/2011 Name of Carrier / Vessel: FX 0007 Date of Certification: 10/24/2011 Signature of Customs Official: [Signature] 01349
IMPORTER/EXPORTER (Name and Address) NEBRASKA STATE PENITENTIARY 4201 14TH SOUTH STREET LINCOLN, NE 68502-0000		BROKER OR FORWARDING AGENT, IF USED (Name and Address) Werner Global Logistics 14507 Frontier Road Omaha, NE 68138
DEA REGISTRATION NO. 0414184		
2. CONTROLLED SUBSTANCES TO BE IMPORTED OR EXPORTED		
2a. NAME AND QUANTITY OF DRUG or PREPARATION <small>(Enter names as shown on labels; numbers and sizes of packages; strength of tablets, capsules, etc., CSA Drug Code and NDC Number)</small> THIOPENTONE INJECTION 1P 1 GM "THIOSOL SODIUM" QTY 500 - 20X25 VIALS CSA DRUG CODE: 2329	2b. CONTROLLED SUBSTANCE CONTENT OF DRUG OR PREPARATION expressed as salt, base or alkaloid. <small>(Enter names of controlled substances contained in the drug; compound, or preparation)</small> THIOSOL SODIUM (THIOPENTONE INJECTION)	2c. DATE IMPORTED/EXPORTED AND ACTUAL QUANTITY <small>(Completed by regulated person of transaction)</small> <div style="text-align: center;">  10/24/2011 479 1GM vials </div>
3. <input checked="" type="checkbox"/> FOREIGN <input type="checkbox"/> DOMESTIC PORT OF EXPORTATION (last U.S. Customs Port) AND APPROX. DEPARTURE DATE Kolkata, India		<input type="checkbox"/> FOREIGN <input checked="" type="checkbox"/> DOMESTIC PORT OF IMPORTATION (first U.S. Customs Port) AND APPROX. ARRIVAL DATE Lincoln, NE 8/15/11
4. MODE OF TRANSPORT; NAME OF VESSEL / CARRIER (if known) Fedex		NAME OF ALL INTERMEDIATE CARRIERS N/A
5. NAME AND ADDRESS OF FOREIGN CONSIGNEE/CONSIGNOR Harris Pharma LLP. 145 B Bosepukur Road Prashanti Building Kolkata West Bengal 700039, India		
I hereby certify that the above named substance(s) to be <input checked="" type="checkbox"/> Imported, <input type="checkbox"/> Exported, are intended for <input type="checkbox"/> Legitimate medical need, <input type="checkbox"/> Scientific research, <input checked="" type="checkbox"/> Other <small>(If intended for reexport beyond the country of destination described in block 5 above, attach documentation per Title 21, CFR 1312.27.)</small> If used as "Export Declaration", attach documentation that Importation is not contrary to the laws or regulations of the country of destination.		
SIGNATURE OF AUTHORIZED INDIVIDUAL OF IMPORTER/EXPORTER, BROKER OR FORWARDING AGENT 		NAME OF FIRM AND TELEPHONE NUMBER State of Nebraska, Dept. of Corrections (402) 479-5630
DATE 7/26/2011		

DEA Form
(Apr. 1988) - 236

Previous edition dated 4/80 is OBSOLETE
COPY 1

WGL-1102368 2
1-3



Ship

Track

Manage

Learn

FedEx Office®

Support Locations English

Search fedex.com



Detailed Results

[Printer-Friendly](#)[Get Link](#)[Help](#)

Enter tracking number

[Track](#)

Detailed Results	Notifications	Associated Shipments																																																																								
<p>This shipment is part of a multiple-piece shipment</p> <p>Master tracking no. 871365493980 Total pieces 2 Total shipment weight 35.0 kg/77.2 lbs</p> <p>View all associated shipments</p>																																																																										
<p>Tracking no.: 871365493980 (2 of 2) Select time format: 12H 24H E-mail notifications</p>																																																																										
<p>In transit</p> <p>Initiated Picked up In transit Delivered</p> <p>At FedEx destination facility LINCOLN, NE</p>																																																																										
<p>Shipment Dates Destination</p> <p>Ship date Oct 12, 2011 LINCOLN, NE</p>																																																																										
<p>Shipment Options Help</p> <p>Hold at FedEx Location Not available to receive your shipment? FedEx will hold your shipment at a nearby FedEx location at no extra cost. Some shipments may not be eligible for this service. Read more.</p>																																																																										
<p>Shipment Facts Help</p> <p>Service type International Priority Service - Indirect Signature Required</p> <p>Pieces 2 of 2 Total Shipment Weight 35.0 kg/77.2 lbs</p>																																																																										
<p>Shipment Travel History Help</p> <p>Select time zone: Local Scan Time</p> <p>All shipment travel activity is displayed in local time for the location</p> <table border="1"> <thead> <tr> <th>Date/Time</th> <th>Activity</th> <th>Location</th> <th>Details</th> </tr> </thead> <tbody> <tr> <td>Oct 24, 2011 9:06 AM</td> <td>At local FedEx facility</td> <td>LINCOLN, NE</td> <td></td> </tr> <tr> <td>Oct 22, 2011 5:50 AM</td> <td>At destination sort facility</td> <td>OMAHA, NE</td> <td></td> </tr> <tr> <td>Oct 22, 2011 4:26 AM</td> <td>Departed FedEx location</td> <td>MEMPHIS, TN</td> <td></td> </tr> <tr> <td>Oct 20, 2011 11:32 PM</td> <td>Arrived at FedEx location</td> <td>MEMPHIS, TN</td> <td></td> </tr> <tr> <td>Oct 20, 2011 11:07 PM</td> <td>In transit</td> <td>PARIS FR</td> <td></td> </tr> <tr> <td>Oct 20, 2011 9:02 PM</td> <td>Departed FedEx location</td> <td>PARIS FR</td> <td></td> </tr> <tr> <td>Oct 20, 2011 5:52 PM</td> <td>Arrived at FedEx location</td> <td>PARIS FR</td> <td></td> </tr> <tr> <td>Oct 20, 2011 12:56 PM</td> <td>In transit</td> <td>NEW DELHI IN</td> <td></td> </tr> <tr> <td>Oct 19, 2011 6:54 PM</td> <td>Left FedEx origin facility</td> <td>KOLKATA IN</td> <td></td> </tr> <tr> <td>Oct 18, 2011 7:00 PM</td> <td>Clearance in progress</td> <td>KOLKATA IN</td> <td></td> </tr> <tr> <td>Oct 17, 2011 11:15 PM</td> <td>Shipment exception</td> <td>KOLKATA IN</td> <td>Delay beyond our control</td> </tr> <tr> <td>Oct 17, 2011 10:14 PM</td> <td>Clearance in progress</td> <td>KOLKATA IN</td> <td></td> </tr> <tr> <td>Oct 15, 2011 8:48 PM</td> <td>Clearance in progress</td> <td>KOLKATA IN</td> <td></td> </tr> <tr> <td>Oct 14, 2011 8:48 PM</td> <td>Clearance in progress</td> <td>KOLKATA IN</td> <td></td> </tr> <tr> <td>Oct 14, 2011 8:00 PM</td> <td>Clearance in progress</td> <td>KOLKATA IN</td> <td></td> </tr> <tr> <td>Oct 13, 2011 7:10 PM</td> <td>Shipment exception</td> <td>KOLKATA IN</td> <td>Improper or missing international paperwork, contact Customer Service</td> </tr> <tr> <td>Oct 12, 2011 9:50 PM</td> <td>Picked up</td> <td>KOLKATA IN</td> <td></td> </tr> </tbody> </table>			Date/Time	Activity	Location	Details	Oct 24, 2011 9:06 AM	At local FedEx facility	LINCOLN, NE		Oct 22, 2011 5:50 AM	At destination sort facility	OMAHA, NE		Oct 22, 2011 4:26 AM	Departed FedEx location	MEMPHIS, TN		Oct 20, 2011 11:32 PM	Arrived at FedEx location	MEMPHIS, TN		Oct 20, 2011 11:07 PM	In transit	PARIS FR		Oct 20, 2011 9:02 PM	Departed FedEx location	PARIS FR		Oct 20, 2011 5:52 PM	Arrived at FedEx location	PARIS FR		Oct 20, 2011 12:56 PM	In transit	NEW DELHI IN		Oct 19, 2011 6:54 PM	Left FedEx origin facility	KOLKATA IN		Oct 18, 2011 7:00 PM	Clearance in progress	KOLKATA IN		Oct 17, 2011 11:15 PM	Shipment exception	KOLKATA IN	Delay beyond our control	Oct 17, 2011 10:14 PM	Clearance in progress	KOLKATA IN		Oct 15, 2011 8:48 PM	Clearance in progress	KOLKATA IN		Oct 14, 2011 8:48 PM	Clearance in progress	KOLKATA IN		Oct 14, 2011 8:00 PM	Clearance in progress	KOLKATA IN		Oct 13, 2011 7:10 PM	Shipment exception	KOLKATA IN	Improper or missing international paperwork, contact Customer Service	Oct 12, 2011 9:50 PM	Picked up	KOLKATA IN	
Date/Time	Activity	Location	Details																																																																							
Oct 24, 2011 9:06 AM	At local FedEx facility	LINCOLN, NE																																																																								
Oct 22, 2011 5:50 AM	At destination sort facility	OMAHA, NE																																																																								
Oct 22, 2011 4:26 AM	Departed FedEx location	MEMPHIS, TN																																																																								
Oct 20, 2011 11:32 PM	Arrived at FedEx location	MEMPHIS, TN																																																																								
Oct 20, 2011 11:07 PM	In transit	PARIS FR																																																																								
Oct 20, 2011 9:02 PM	Departed FedEx location	PARIS FR																																																																								
Oct 20, 2011 5:52 PM	Arrived at FedEx location	PARIS FR																																																																								
Oct 20, 2011 12:56 PM	In transit	NEW DELHI IN																																																																								
Oct 19, 2011 6:54 PM	Left FedEx origin facility	KOLKATA IN																																																																								
Oct 18, 2011 7:00 PM	Clearance in progress	KOLKATA IN																																																																								
Oct 17, 2011 11:15 PM	Shipment exception	KOLKATA IN	Delay beyond our control																																																																							
Oct 17, 2011 10:14 PM	Clearance in progress	KOLKATA IN																																																																								
Oct 15, 2011 8:48 PM	Clearance in progress	KOLKATA IN																																																																								
Oct 14, 2011 8:48 PM	Clearance in progress	KOLKATA IN																																																																								
Oct 14, 2011 8:00 PM	Clearance in progress	KOLKATA IN																																																																								
Oct 13, 2011 7:10 PM	Shipment exception	KOLKATA IN	Improper or missing international paperwork, contact Customer Service																																																																							
Oct 12, 2011 9:50 PM	Picked up	KOLKATA IN																																																																								
<div> <p>Stay in the know. Get notifications when a delivery requires your signature.</p> <p>Sign up now ></p> </div> <div> <p>FedEx Advanced Tracking: The ultimate in tracking visibility.</p> <p>Watch demo ></p> </div>																																																																										



Search fedex.com



Customer Focus

- New Customer Center
- Small Business Center
- Service Guide
- Customer Support
- My FedEx Rewards

Featured Services

- FedEx SameDay
- FedEx Home Delivery
- Healthcare Solutions
- Online Retail Solutions
- Packaging Services
- Airway Clearance Services

Companies

- FedEx Express
- FedEx Ground
- FedEx Office
- FedEx Freight
- FedEx Custom Critical
- FedEx Trade Networks

Follow FedEx



United States - English



Ship

Track

Manage

Learn

FedEx Office®

Support Locations English

Search fedex.com



Track



- 1 Track by Tracking Number
- 2 Track by Reference
- 3 Track by E-mail
- 4 Obtain Signature Proof of Delivery
- 5 FedEx Desktop
- 6 My FedEx
- 7 TCN
- 8 FedEx InSight
- 9 FedEx Trade Networks
- 10 FedEx Wireless Solution

Won't be around for delivery? Have us hold your shipments for pickup.

[See options](#)

FedEx Tracking:
Learn more about the new features.

[View demo](#)

Obtain Signature Proof of Delivery

[Help](#)

Proof-of-delivery details appear below; however, no signature is currently available for this FedEx Express® shipment. Please check again later for a signature.

Shipment Information

Tracking number:	871365493980	Ship date:	Oct 19, 2011
Status:	Delivered	Weight:	6.1 lbs/2.8 kg
Signed for by:	S. UROSEVICH	Delivery location:	LINCOLN, NE
Service type:	International Priority Service	Delivery date:	Oct 24, 2011

Account number

If account number is not entered or it does not match the shipper or third party payor account number, then only limited SPOD information will be provided.

Your next step

- ☒ View/print letter (no signature)
- ☐ E-mail letter (no signature)
- ☐ Fax letter (no signature)
- ☐ Make a new request

[Continue >>](#)

Please note:

If you have any questions about this shipment, please [contact us](#).



Search fedex.com



Customer Focus

New Customer Center
Small Business Center
Service Guide
Customer Support
My FedEx Rewards

Company Information

About FedEx
Careers
Investor Relations

Featured Services

FedEx SameDay
FedEx Home Delivery
Healthcare Solutions
Online Retail Solutions
Packaging Services
Ancillary Clearance Services

Other Resources

Compatible Solutions Program
Developer Resource Center
FedEx Ship Manager Software
FedEx Mobile


Companies


FedEx Express
FedEx Ground
FedEx Office
FedEx Freight
FedEx Custom Critical
FedEx Trade Networks
FedEx SupplyChain


Follow FedEx



United States - English

U. S. Department of Justice / Drug Enforcement Administration		OMB APPROVAL No. 1117 - 0009
CONTROLLED SUBSTANCES IMPORT / EXPORT DECLARATION		See reverse for Privacy Act
(Read Instructions on reverse before completing)		
<div>1. CHECK ONE <input checked="" type="checkbox"/> IMPORT DECLARATION Nonnarcotic Substances in Schedules III, IV, V <input type="checkbox"/> EXPORT DECLARATION Nonnarcotic Substances in Schedules III, and IV and all substances in Schedule V</div>		U.S. CUSTOMS CERTIFICATION
IMPORTER/EXPORTER (Name and Address) NEBRASKA STATE PENITENTIARY 4201 14TH SOUTH STREET LINCOLN, NE 68502-0000		Date of Departure / Arrival
DEA REGISTRATION NO. 0414184		Name of Carrier / Vessel
BROKER OR FORWARDING AGENT, IF USED (Name and Address) Werner Global Logistics 14507 Frontier Road Omaha, NE 68138		Date of Certification
		Signature of Customs Official
2. CONTROLLED SUBSTANCES TO BE IMPORTED OR EXPORTED		
2a. NAME AND QUANTITY OF DRUG or PREPARATION (Enter names as shown on labels; numbers and sizes of packages; strength of tablets, capsules, etc., CSA Drug Code and NDC Number)	2b. CONTROLLED SUBSTANCE CONTENT OF DRUG OR PREPARATION expressed as acid, base or alkaloid. (Enter names of controlled substances contained in the drug; compound, or preparation)	2c. DATE IMPORTED/EXPORTED AND ACTUAL QUANTITY (Completed by registrant at time of transaction)
THIOPENTONE INJECTION 1P 1 GM "THIOSOL SODIUM" QTY 500 - 20X25 VIALS CSA DRUG CODE: 2329	THIOSOL SODIUM (THIOPENTONE INJECTION)	
3. <input checked="" type="checkbox"/> FOREIGN <input type="checkbox"/> DOMESTIC PORT OF EXPORTATION (last U.S. Customs Port) AND APPROX. DEPARTURE DATE Kolkata, India		<input type="checkbox"/> FOREIGN <input checked="" type="checkbox"/> DOMESTIC PORT OF IMPORTATION (first U.S. Customs Port) AND APPROX. ARRIVAL DATE Lincoln, NE 8/15/11
4. MODE OF TRANSPORT; NAME OF VESSEL / CARRIER (if known) Fedex		NAME OF ALL INTERMEDIATE CARRIERS N/A
5. NAME AND ADDRESS OF FOREIGN CONSIGNEE/CONSIGNOR Harris Pharma LLP. 145 B Bosepukur Road Prashanti Building Kolkata West Bengal 700039, India		
I hereby certify that the above named substance(s) to be <input checked="" type="checkbox"/> Imported, <input type="checkbox"/> Exported, are intended for <input type="checkbox"/> Legitimate medical need, <input type="checkbox"/> Scientific research, <input checked="" type="checkbox"/> Other (If intended for reexport beyond the country of destination described in block 5 above, attach documentation per Title 21, CFR 1312.27.) If used as "Export Declaration", attach documentation that importation is not contrary to the laws or regulations of the country of destination.		
SIGNATURE OF AUTHORIZED INDIVIDUAL OF IMPORTER/EXPORTER, BROKER OR FORWARDING AGENT 	DATE 7/26/2011	NAME OF FIRM AND TELEPHONE NUMBER State of Nebraska, Dept. of Corrections (402) 479-5630

U. S. Department of Justice / Drug Enforcement Administration		OMB APPROVAL No. 1117 - 0009
CONTROLLED SUBSTANCES IMPORT / EXPORT DECLARATION		See reverse for Privacy Act
(Read Instructions on reverse before completing)		
1. CHECK ONE <input checked="" type="checkbox"/> IMPORT DECLARATION Nonnarcotic Substances in Schedules III, IV, V <input type="checkbox"/> EXPORT DECLARATION Nonnarcotic Substances in Schedules III, and IV and all substances in Schedule V		U.S. CUSTOMS CERTIFICATION Date of Departure / Arrival
IMPORTER/EXPORTER (Name and Address) STATE OF NEBRASKA, DEPT. OF CORRECTIONS PO BOX 94661 LINCOLN, NE 68509 DEA REGISTRATION NO. AN 5903453		BROKER OR FORWARDING AGENT, IF USED (Name and Address) PHIL PATTERSON, INC. 1209 HARNEY ST. OMAHA, NE 68102
		Name of Carrier / Vessel Date of Certification Signature of Customs Official
2. CONTROLLED SUBSTANCES TO BE IMPORTED OR EXPORTED		
2a. NAME AND QUANTITY OF DRUG or PREPARATION (Enter names as shown on labels; numbers and sizes of packages; strength of tablets, capsules, etc., CSA Drug Code and NDC Number)	2b. CONTROLLED SUBSTANCE CONTENT OF DRUG OR PREPARATION expressed as acid, base or alkaloid. (Enter names of controlled substances contained in the drug, compound, or preparation)	2c. DATE IMPORTED/EXPORTED AND ACTUAL QUANTITY (Completed by registrant at time of transaction)
THIOPENTONE INJECTION IP 1 GM "THIOSOL SODIUM" QTY 500 - 20X25 VIALS DRUG LICENSE NUMBER 21BZ-7/103/2135	THIOSOL SODIUM (THIOPENTONE INJECTION)	
3. <input checked="" type="checkbox"/> FOREIGN <input type="checkbox"/> DOMESTIC PORT OF EXPORTATION (last U.S. Customs Port) AND APPROX. DEPARTURE DATE MUMBAI (BOMBAY) INDIA 12/09/10		<input type="checkbox"/> FOREIGN <input checked="" type="checkbox"/> DOMESTIC PORT OF IMPORTATION (first U.S. Customs Port) AND APPROX. ARRIVAL DATE NEWARK, NJ 12/12/10
4. MODE OF TRANSPORT; NAME OF VESSEL / CARRIER (if known) AIR - CONTINENTAL AIRLINES FLT CO049		NAME OF ALL INTERMEDIATE CARRIERS CEVA LOGISTICS - TRUCKER FROM NEWARK
5. NAME AND ADDRESS OF FOREIGN CONSIGNEE/CONSIGNOR NEON LABORATORIES LTD 143 DAMJI SHAMJI INDUSTRIAL COMPLEX CHAKALA M.I.D.C., MUMBAI MAHARASHTRA 400093, INDIA		
I hereby certify that the above named substance(s) to be <input checked="" type="checkbox"/> Imported, <input type="checkbox"/> Exported, are intended for <input type="checkbox"/> Legitimate medical need, <input type="checkbox"/> Scientific research, <input checked="" type="checkbox"/> Other (If intended for reexport beyond the country of destination described in block 5 above, attach documentation per Title 21, CFR 1312.27.) If used as "Export Declaration", attach documentation that importation is not contrary to the laws or regulations of the country of destination.		
SIGNATURE OF AUTHORIZED INDIVIDUAL OF IMPORTER/EXPORTER, BROKER OR FORWARDING AGENT 	DATE Dec 14, 2010	NAME OF FIRM AND TELEPHONE NUMBER STATE OF NEBRASKA, DEPT. OF CORRECTIONS (402) 479-5630

U. S. Department of Justice / Drug Enforcement Administration		OMB APPROVAL No. 1117 - 0009	
CONTROLLED SUBSTANCES IMPORT / EXPORT DECLARATION			
(Read Instructions on reverse before completing)		See reverse for Privacy Act	
1. CHECK ONE <input checked="" type="checkbox"/> IMPORT DECLARATION Nonnarcotic Substances in Schedules III, IV, V <input type="checkbox"/> EXPORT DECLARATION Nonnarcotic Substances in Schedules III, and IV and all substances in Schedule V		U.S. CUSTOMS CERTIFICATION	
		Date of Departure / Arrival	
IMPORTER/EXPORTER (Name and Address) STATE OF NEBRASKA, DEPT. OF CORRECTIONS PO BOX 94661 LINCOLN, NE 68509 DEA REGISTRATION NO. AN 5903453		Name of Carrier / Vessel	
		Date of Certification	
		Signature of Customs Official	
BROKER OR FORWARDING AGENT, IF USED (Name and Address) PHIL PATTERSON, INC. 1209 HARNEY ST. OMAHA, NE 68102			
2. CONTROLLED SUBSTANCES TO BE IMPORTED OR EXPORTED			
2a. NAME AND QUANTITY OF DRUG or PREPARATION (Enter names as shown on labels; numbers and sizes of packages; strength of tablets, capsules, etc.; CSA Drug Code and NDC Number)		2b. CONTROLLED SUBSTANCE CONTENT OF DRUG OR PREPARATION expressed as acid, base or alkaloid. (Enter names of controlled substances contained in the drug; compound, or preparation)	
THIOPENTONE INJECTION IP 1 GM "THIOSOL SODIUM" QTY 500 - 20X25 VIALS DRUG LICENSE NUMBER 21BZ-7/103/2135		THIOSOL SODIUM (THIOPENTONE INJECTION)	
3. <input checked="" type="checkbox"/> FOREIGN <input type="checkbox"/> DOMESTIC PORT OF EXPORTATION (last U.S. Customs Port) AND APPROX. DEPARTURE DATE MUMBAI (BOMBAY) INDIA 12/09/10		<input type="checkbox"/> FOREIGN <input checked="" type="checkbox"/> DOMESTIC PORT OF IMPORTATION (first U.S. Customs Port) AND APPROX. ARRIVAL DATE NEWARK, NJ 12/12/10	
4. MODE OF TRANSPORT; NAME OF VESSEL / CARRIER (if known) AIR - CONTINENTAL AIRLINES FLT 00049		NAME OF ALL INTERMEDIATE CARRIERS CEVA LOGISTICS - TRUCKER FROM NEWARK	
5. NAME AND ADDRESS OF FOREIGN CONSIGNEE/CONSIGNOR NEON LABORATORIES LTD 143 DAMJI SHAMJI INDUSTRIAL COMPLEX CHAKALA M.I.D.C., MUMBAI MAHARASHTRA 400093, INDIA			
I hereby certify that the above named substance(s) to be <input checked="" type="checkbox"/> Imported, <input type="checkbox"/> Exported, are intended for <input type="checkbox"/> Legitimate medical need, <input type="checkbox"/> Scientific research, <input checked="" type="checkbox"/> Other (If intended for reexport beyond the country of destination described in block 5 above, attach documentation per Title 21, CFR 1312.27.) If used as "Export Declaration", attach documentation that importation is not contrary to the laws or regulations of the country of destination.			
SIGNATURE OF AUTHORIZED INDIVIDUAL OF IMPORTER/EXPORTER, BROKER OR FORWARDING AGENT 		DATE Dec 14, 2010	NAME OF FIRM AND TELEPHONE NUMBER STATE OF NEBRASKA, DEPT. OF CORRECTIONS (402) 479-5630

CONTROLLED SUBSTANCES IMPORT / EXPORT DECLARATION

(Read Instructions on reverse before completing)

OMB APPROVAL
No. 1117 - 0009

See reverse for Privacy Act


1. CHECK ONE <input checked="" type="checkbox"/> IMPORT DECLARATION <input type="checkbox"/> EXPORT DECLARATION	Nonnarcotic Substances in Schedules III, IV, V	U.S. CUSTOMS CERTIFICATION
	Nonnarcotic Substances in Schedules III, and IV and all substances in Schedule V	
IMPORTER/EXPORTER (Name and Address) STATE OF NEBRASKA, DEPT. OF CORRECTIONS PO BOX 94661 LINCOLN, NE 68509		Date of Departure / Arrival
BROKER OR FORWARDING AGENT, IF USED (Name and Address) PHIL PATTERSON, INC. 1209 HARNEY ST. OMAHA, NE 68102		Name of Carrier / Vessel
DEA REGISTRATION NO. AN 5903453		Date of Certification
2. CONTROLLED SUBSTANCES TO BE IMPORTED OR EXPORTED		Signature of Customs Official

2a. NAME AND QUANTITY OF DRUG or PREPARATION (Enter names as shown on labels; numbers and sizes of packages; strength of tablets, capsules, etc., CSA Drug Code and NDC Number)	2b. CONTROLLED SUBSTANCE CONTENT OF DRUG OR PREPARATION expressed as acid, base or alkaloid (Enter names of controlled substances contained in the drug, compound, or preparation)	2c. DATE IMPORTED/EXPORTED AND ACTUAL QUANTITY (Completed by registrant at time of transaction)
THIOPENTONE INJECTION IP 1 GM "THIOSOL SODIUM" QTY 500 - 20X25 VIALS DRUG LICENSE NUMBER 21BZ-7/103/2135	THIOSOL SODIUM (THIOPENTONE INJECTION)	

3. <input checked="" type="checkbox"/> FOREIGN <input type="checkbox"/> DOMESTIC PORT OF EXPORTATION (last U.S. Customs Port) AND APPROX. DEPARTURE DATE MUMBAI (BOMBAY) INDIA 12/09/10	<input type="checkbox"/> FOREIGN <input checked="" type="checkbox"/> DOMESTIC PORT OF IMPORTATION (first U.S. Customs Port) AND APPROX. ARRIVAL DATE NEWARK, NJ 12/12/10
4. MODE OF TRANSPORT; NAME OF VESSEL / CARRIER (if known) AIR - CONTINENTAL AIRLINES FLT 00049	NAME OF ALL INTERMEDIATE CARRIERS CEVA LOGISTICS - TRUCKER FROM NEWARK
5. NAME AND ADDRESS OF FOREIGN CONSIGNEE/CONSIGNOR NEON LABORATORIES LTD 143 DAMJI SHAMJI INDUSTRIAL COMPLEX CHAKALA M.I.D.C., MUMBAI MAHARASHTRA 400093, INDIA	

I hereby certify that the above named substance(s) to be ☒ Imported, ☐ Exported, are intended for ☐ Legitimate medical need, ☐ Scientific research, ☒ Other (If intended for reexport beyond the country of destination described in block 5 above, attach documentation per Title 21, CFR 1312.27.)

If used as "Export Declaration", attach documentation that importation is not contrary to the laws or regulations of the country of destination.

SIGNATURE OF AUTHORIZED INDIVIDUAL OF IMPORTER/EXPORTER, BROKER OR FORWARDING AGENT 	DATE Dec 14, 2010	NAME OF FIRM AND TELEPHONE NUMBER STATE OF NEBRASKA, DEPT. OF CORRECTIONS (402) 479-5630
---	----------------------	--

CONTROLLED SUBSTANCES IMPORT / EXPORT DECLARATION

(Read Instructions on reverse before completing)

OMB APPROVAL
No. 1117 - 0009

See reverse for Privacy Act

1. CHECK ONE ☒ IMPORT DECLARATION Nonnarcotic Substances in Schedules III, IV, V
☐ EXPORT DECLARATION Nonnarcotic Substances in Schedules III, and IV and all substances in Schedule V

IMPORTER/EXPORTER (Name and Address)

STATE OF NEBRASKA, DEPT. OF
CORRECTIONS
PO BOX 94661
LINCOLN, NE 68509

BROKER OR FORWARDING AGENT, IF USED

(Name and Address)
PHIL PATTERSON, INC.
1209 HARNEY ST.
OMAHA, NE 68102U.S. CUSTOMS
CERTIFICATION

Date of Departure / Arrival

Name of Carrier / Vessel

Date of Certification

Signature of Customs Official

DEA REGISTRATION NO. AN 5903453

2. CONTROLLED SUBSTANCES TO BE IMPORTED OR EXPORTED

2a. NAME AND QUANTITY OF DRUG or PREPARATION
(Enter names as shown on labels; numbers and sizes
of packages; strength of tablets, capsules, etc.,
CSA Drug Code and NDC Number)THIOPENTONE INJECTION IP 1 GM
"THIOSOL SODIUM"

QTY 500 - 20X25 VIALS

DRUG LICENSE NUMBER 21BZ-7/103/2135

2b. CONTROLLED SUBSTANCE CONTENT OF DRUG
OR PREPARATION expressed as acid, base or
alkaloid (Enter names of controlled substances
contained in the drug; compound, or preparation)THIOSOL SODIUM (THIOPENTONE
INJECTION)2c. DATE IMPORTED/EXPORTED
AND ACTUAL QUANTITY
(Completed by registrant at time
of transaction)3. ☒ FOREIGN ☐ DOMESTIC PORT OF EXPORTATION (last U.S.
Customs Port) AND APPROX. DEPARTURE DATE
MUMBAI (BOMBAY) INDIA 12/09/10☐ FOREIGN ☒ DOMESTIC PORT OF IMPORTATION (first U.S.
Customs Port) AND APPROX. ARRIVAL DATE
NEWARK, NJ 12/12/104. MODE OF TRANSPORT; NAME OF VESSEL / CARRIER (if known)
AIR - CONTINENTAL AIRLINES FLT 0049NAME OF ALL INTERMEDIATE CARRIERS
CEVA LOGISTICS - TRUCKER FROM NEWARK5. NAME AND ADDRESS OF FOREIGN CONSIGNEE/CONSIGNOR
NEON LABORATORIES LTD
143 DAMJI SHAMJI INDUSTRIAL COMPLEX
CHAKALA M.I.D.C., MUMBAI MAHARASHTRA 400093, INDIA

I hereby certify that the above named substance(s) to be ☒ Imported, ☐ Exported, are intended for ☐ Legitimate medical need, ☐ Scientific research,
☒ Other (If intended for reexport beyond the country of destination described in block 5 above, attach documentation per Title 21, CFR 1312.27.)

If used as "Export Declaration", attach documentation that importation is not contrary to the laws or regulations of the country of destination.

SIGNATURE OF AUTHORIZED INDIVIDUAL OF IMPORTER/
EXPORTER, BROKER OR FORWARDING AGENT

DATE

Dec 14, 2010

NAME OF FIRM AND TELEPHONE NUMBER

STATE OF NEBRASKA, DEPT. OF CORRECTIONS

(402) 479-5630

**Sodium Thiopental: Transaction documents
for second shipment**

Transaction Documents

❖ 2 e-mails from Aaditya Sinha with NAARI and Jagsonpal to Chris Harris:

1. Dated September 29, 2011 confirming they are “really happy” to be able to send Harris 500 vials of Thiopental Sodium. Further they indicate “you can send check for 500 vials as follows” in favor of Jagsonpal Pharmaceuticals and Harris pays the courier.
2. Dated October 1, 2011 confirming they received the check for 485 vials of Sodium Thiopental in the amount of 20,475 rupees

❖ Purchase Order from Harris Pharma to NAARI dated September 15, 2011 for 486 vials of Thiopental Sodium (1 vial was broken in shipment) which matches the 485 we received. The amount of Purchase order does not include courier charges

❖ Check dated 10/01/2011 from Axis Bank and Harris Pharma to Jagsonpal Pharmaceuticals in the amount of 20,475 Rupees. The amount coincides with the stated price of 20,475 indicated in the October 1, 2011 e-mail from Harris to Aaditya Sinha with NAARI

❖ Axis bank account statement for Harris Pharma which indicates the check to Jagsonpal was cashed on October 20, 2011 in the amount of 20,475 Rupees.

Urosevich, Steve

From: Chris Harris <chrisharris@harrispharmallp.com>
Sent: Thursday, January 05, 2012 3:09 AM
To: Urosevich, Steve
Subject: Fw: Samples TPS & Address JPPL

From: Aaditya Sinha
Sent: Thursday, September 29, 2011 10:23 PM
To: Chris Harris
Subject: Samples TPS & Address JPPL

Dear Chris

I am really happy that at last I am able to send you 500 vials of Thiopental Sodium. But, I am really sorry for unavailability of 2000 samples, any how I hope in future I can supply you as much vials as possible.

You can send the cheque for 500 vials as follows:

- Rs 35 X 500 = Rs 16, 500 cheque in favor of Jagsonpal Pharmaceuticals Ltd. (In this case you can pay the courier charges in Kolkata itself)
- Rs 35 X 500 = Rs 16, 500 + Rs 3, 500 (Approx) = Rs 20, 000 in favor of Jagsonpal Pharmaceuticals Ltd. (In case we pay the courier charges here in Noida)

Please confirm which way you would like to pay so that I can send you my Invoice accordingly. Also, I request you to send us a purchase order for 500 vials, in favor of Jagsonpal Pharmaceuticals Ltd. for our records.

You can send the cheque on the following address:

Attn: Aaditya Sinha
Jagsonpal Pharmaceuticals Ltd.
C-82, Hosiery Complex
Phase II, Noida – 201305
India
Tel: 0120-4070732

Look forward for your response.

Thanks & Regards
Aaditya P. Sinha
Business Development
Web Link – www.naari.ch

NAARI
Empowering Women

Arnold Bocklin - Strasse 11
4051 Basel
Switzerland
Tel.: +41 615880242
Fax: +41 615880226
Mob: +91 9811105979
Skype: aaditya.sinha_naari

Urosevich, Steve

From: Chris Harris <chrisharris@harrispharmallp.com>
Sent: Thursday, January 05, 2012 3:09 AM
To: Urosevich, Steve
Subject: Fw: Cheque

From: Aaditya Sinha
Sent: Saturday, October 01, 2011 11:09 PM
To: Chris Harris
Subject: RE: Cheque

Thanks Chris, got the Cheque. Will get the order executed within 60 days starting 3rd October i.e. you will get the orders by December 3, 2011.

Cheers for our successful start of bright business association.

Thanks & Regards
Aaditya Sinha

From: Chris Harris [<mailto:chrisharris@harrispharmallp.com>]
Sent: Saturday, October 01, 2011 8:28 PM
To: Aaditya Sinha
Subject: Cheque

Hi Aaditya,

This is to confirm the order for Sodium Thiopental 20,000 Vials. I will send you a cheque of Rs 3 Lacks as advance for the order on 7th Oct when I return.

I will also send a check of Rs 20,475 as payment for 485 Vials Sodium Thiopental.

Pls find scanned copy of cheque's attached.

Regards,
Chris Harris
CEO
Harris Pharma LLP.
145 B Bosepukur Road,
Prashanti Building,
Kolkata 700039
West Bengal,
India
Phone (Direct): +(91)-33-40614353
Cell: +(91)-9836827779
www.harrispharmallp.com

DISCLAIMER:

Urosevich, Steve

From: Chris Harris <chrisharris@harrispharmallp.com>
Sent: Friday, December 02, 2011 1:41 PM
To: Urosevich, Steve
Subject: Re: News of Interest
Attachments: Cheque.pdf; Naari Purchase Order 486 Vials.pdf

Hi Steve,

Pls find attached the cheque paid for the product. In the attachment is two cheques. The second one is the one for the 485 vials. I am also attaching the purchase order for it. Check is for a little more then purchase order as it included courier charges to my office. You will find the cheque is in the name of Jagsonpal. The reason for this is that Jagsonpal is the indian branch of Naari and they are the ones who accept payment in Indian rupees.

Regards,
Chris Harris
CEO
Harris Pharma LLP.
145 B Bosepukur Road,
Prashanti Building,
Kolkata 700039
West Bengal,
India
Phone (Direct): +(91)-33-40614353
Cell: +(91)-9836827779
www.harrispharmallp.com

DISCLAIMER:

Information contained and transmitted by this E-MAIL including any attachment is proprietary to Harris Pharma LLP and is intended solely for the addressee/s, and may contain information that is privileged, confidential or exempt from disclosure under applicable law. Access to this e-mail and/or to the attachment by anyone else is unauthorized. If this is a forwarded message, the content and the views expressed in this E-MAIL may not reflect those of the Company. If you are not the intended recipient, an agent of the intended recipient or a person responsible for delivering the information to the named recipient, you are notified that any use, distribution, transmission, printing, copying or dissemination of this information in any way or in any manner is strictly prohibited. If you are not the intended recipient of this mail kindly delete from your system and inform the sender. There is no guarantee that the integrity of this communication has been maintained and nor is this communication free of viruses, interceptions or interference.

From: Urosevich, Steve
Sent: Thursday, December 01, 2011 7:49 PM
To: chrisharris@harrispharmallp.com
Subject: Re: News of Interest



HarrisPharma

manufacturer and distribution services

PURCHASE ORDER

To

NAARI
Arnold Bocklin - Strasse 11
4051 Basel
Switzerland

Issued By:

Harris Pharma LLP.
145 B Bosepukur Road,
Prashanti Building,
Kolkata 700039
West Bengal, India

Dated: Sep 15, 2011

Sub: Purchase Order

S.No.	Product	Quantity	Unit Price	Amount in Rupees
1	Anes 1.0 (Thiopental Sodium, 1.0 g)	42Vials	Rs 35/ Vial	1470.00
	Daffotal (Thiopental Sodium, 1.0g)	444Vials	Rs 35/ Vial	15540.00
			Total in Rupees	17010.00

Total: Seventeen Thousand and Ten Rupees Only

Terms & Conditions:

- Payment Terms: 100% Advance
- Delivery: 15 Days from the day of Purchase Order

For,

Harris Pharma LLP


Chris Harris
CEO



145B Bosepukur Road, Kolkata 700039, West Bengal, India, Ph : +91-33-40614353



AXIS BANK LTD

GOLPARK, KOLKATA (WB), KOLKATA 700019
IFS CODE - UTIB0000011

New Account

DATE
दिनांक

0	1	2	3	4	5	6	7	8	9
---	---	---	---	---	---	---	---	---	---

PAY

Jagsonpal PHARMACEUTICALS LTD

OR BEARER / या धारक को

RUPEES
रुपये

Twenty thousand four hundred and seventy
thru only.

अथ कैं

₹ 20,475/-

A/C NO.

CANOR 011260

For HARRIS PHARMA LLP

HARRIS PHARMALLP

Designated/Authorised Signatory
प्रतिनिधित्व/अनुमोदित हस्ताक्षर

[Signature]

[Signature]

011260

10

10

1

THIS WARRANT IS VOID WITHOUT A COLORED BACKGROUND AND AN ARTIFICIAL WATERMARK CERTIFICATION SEAL ON THE BACK - HOLD AT ANGLE TO VIEW SEAL

STATE OF NEBRASKA
TREASURY WARRANT

STATE OF NEBRASKA
TREASURY WARRANT

20645882

PAY TO THE ORDER OF HARRIS PHARMA LLP
WESTBENEFIT

AMOUNT ALTERNATION VOIDS WARRANT

\$5411.00


VOID AFTER ONE YEAR

FIVE THOUSAND FOUR HUNDRED ELEVEN AND 00/100

STATE TREASURER

TWO SIGNATURES REQUIRED

DIRECTOR OF ADMINISTRATIVE SERVICES



20645882 121040000904

020645882



Handwritten signature

Williams, Bettyjo

From: Chris Harris (Harris Pharma LLP) <chrisharris@harrispharmallp.com>
Sent: Wednesday, May 11, 2011 6:02 AM
To: Urosevich, Steve
Subject: Supply

Hi Steve,

This is to state that my company is willing and capable of supplying the required pharmaceutical products for the Department of Corrections Nebraska. Specifically Sodium Thiopental for a period of 5 years.

Regards,
Chris Harris
CEO
Harris Pharma LLP.
145 B Bosepukur Road,
Prashanti Building,
Kolkata 700039
West Bengal,
India
Phone (Direct): +(91)-33-40614353
Cell: +(91)-9836827779
US: +1-239 494 5670
Fax: +(1)-800-6526916
www.harrispharmallp.com

DISCLAIMER:

Information contained and transmitted by this E-MAIL including any attachment is proprietary to Harris Pharma LLP and is intended solely for the addressee/s, and may contain information that is privileged, confidential or exempt from disclosure under applicable law. Access to this e-mail and/or to the attachment by anyone else is unauthorized. If this is a forwarded message, the content and the views expressed in this E-MAIL may not reflect those of the Company. If you are not the intended recipient, an agent of the intended recipient or a person responsible for delivering the information to the named recipient, you are notified that any use, distribution, transmission, printing, copying or dissemination of this information in any way or in any manner is strictly prohibited. If you are not the intended recipient of this mail kindly delete from your system and inform the sender. There is no guarantee that the integrity of this communication has been maintained and nor is this communication free of viruses, interceptions or interference.

Williams, Bettyjo

From: Chris Harris (Harris Pharma LLP) <chrisharris@harrispharmallp.com>
Sent: Wednesday, May 25, 2011 3:45 AM
To: Urosevich, Steve
Subject: Fw:
Attachments: Form 236.pdf

Hi Steve,

Pls find the forwarded mail attached with the Form 236.

Regards,
Chris Harris
CEO
Harris Pharma LLP.
171B/1F Picnic Garden Road,
Kolkata 700039
West Bengal,
India
Phone (Direct): +(91)-33-40614353
Cell: +(91)-9836827779
US: +1-239 494 5670
Fax: +(1)-800-6526916
www.harrispharmallp.com

DISCLAIMER:

Information contained and transmitted by this E-MAIL including any attachment is proprietary to Harris Pharma LLP and is intended solely for the addressee/s, and may contain information that is privileged, confidential or exempt from disclosure under applicable law. Access to this e-mail and/or to the attachment by anyone else is unauthorized. If this is a forwarded message, the content and the views expressed in this E-MAIL may not reflect those of the Company. If you are not the intended recipient, an agent of the intended recipient or a person responsible for delivering the information to the named recipient, you are notified that any use, distribution, transmission, printing, copying or dissemination of this information in any way or in any manner is strictly prohibited. If you are not the intended recipient of this mail kindly delete from your system and inform the sender. There is no guarantee that the integrity of this communication has been maintained and nor is this communication free of viruses, interceptions or interference.

----- Original Message -----

From: Elliot Safdie
To: Chris Harris (Harris Pharma LLP)
Sent: Wednesday, May 25, 2011 4:41 AM
Subject: RE:

Hi Chris,

Thanks again for your help.
Attached please find a copy of the new Form-236.
I have sent this out to you again via FedEx.
Please forward this on to the appropriate parties.

Just to clarify – the exportation for this first shipment will be for 1700 vials and the exportation will be made by Ganpati, correct?

Williams, Bettyjo

From: Chris Harris (Harris Pharma LLP) <chrisharris@harrispharmallp.com>
Sent: Monday, July 18, 2011 2:15 PM
To: Urosevich, Steve
Subject: Form 236
Attachments: Original Cert of Incorporation.pdf

Hi Steve,

The details for the form 236 are mentioned below. I am also attaching the new certificate of incorporation of my company. However shipments can only be done first week of August. Also we will have to do a minimum order of 500 Vials at the rate of INR 450 per Vial. This is just to cover my legal expences as I am 100% sure Reprive will be filing a case against my company although in the end I will win it but it is a very long drawn and expensive affair.

Harris Pharma LLP,
145B Bosepukur Road,
Kolkata 700039
West Bengal,
India

I am mentioning my company bank account details below for the Payment. Once you confirm the order will send you the Invoice.

ACCOUNT NAME- Harris Pharma LLP

A/C No. ~~XXXXXXXXXXXX~~ 683

AXISINBB011 (Swift code of Axis Bank)

Axis Bank Ltd.
Golpark Branch
20.Gariahat Road.
Kolkata-700019
India.
Ph No: 24400853/0854/9990

Regards,

Chris Harris

CEO

Harris Pharma LLP.
145B Bosepukur Road,
Kolkata 700039
West Bengal,
India

Phone (Direct): +(91)-33-40614353

Cell: +(91)-9836827779

US: +1-239 494 5670

Fax: +(1)-800-6526916

www.harrispharmallp.com

DISCLAIMER:



प्ररूप 16

(अधिनियम की धारा 12(1)(ख) देखें)
निगमन प्रमाण पत्र

एलएलपी पहचान संख्या : AAA-5194

2011

मैं, यह प्रमाणित करता हूँ कि सीमित दायित्व भागीदारी अधिनियम, 2008 की धारा 12(1) के अंतर्गत आज

Harris Pharma LLP

को निगमित किया गया है।

मेरे हस्ताक्षर से आज 15th day of June, Two Thousand Eleven को दिया गया।

Form 16

[Refer Section 12(1) (b) of the Act]

Certificate of Incorporation

LLP Identity Number : AAA-5194

2011

I hereby certify that **Harris Pharma LLP** is incorporated, pursuant to section 12(1) of the Limited Liability Partnership Act 2008.

Given under my hand at Delhi this 15th day of June, Two Thousand Eleven.

B. Srikumar
(B. Srikumar)
Asst. Registrar

Address:-
Harris Pharma LLP
145B Bose pukur Road

Kolkata
West Bengal-700039



From: Chris Harris (Harris Pharma LLP) (chrisharris@harrispharmallp.com)
To: steveurosevich@yahoo.com;
Date: Wed, July 20, 2011 12:46:04 PM
Cc:
Subject: Re: Form 236

Hi Patrick,

The information you require is mentioned below. The ones not mentioned will be getting on thursday.

1. broker : N/A (unless you are using a broker or forwarding agent.)
2. Customs Port and approximate arrival date : (Customs port of arrival will have on thursday. As for date of arrival will only be able to say after I get the info from the air cargo companies which is thursday.)
3. Mode of transport : (This info I can give you tomorrow as I am speaking to Fedex and another air cargo carrier. Will have this info from them on thursday.)
4. Name of all intermediate carriers : N/A

Regards,
Chris Harris
CEO
Harris Pharma LLP.
145B Bosepukur Road,
Kolkata 700039
West Bengal,
India
Phone (Direct): +(91)-33-40614353
Cell: +(91)-9836827779
US: +1-239 494 5670
Fax: +(1)-800-6526916
www.harrispharmallp.com

DISCLAIMER:

Information contained and transmitted by this E-MAIL including any attachment is proprietary to Harris Pharma LLP and is intended solely for the addressee/s, and may contain information that is privileged, confidential or exempt from disclosure under applicable law. Access to this e-mail and/or to the attachment by anyone else is unauthorized. If this is a forwarded message, the content and the views expressed in this E-MAIL may not reflect those of the Company. If you are not the intended recipient, an agent of the intended recipient or a person responsible for delivering the information to the named recipient, you are notified that any use, distribution, transmission, printing, copying or dissemination of this information in any way or in any manner is strictly prohibited. If you are not the intended recipient of this mail kindly delete from your system and inform the sender. There is no guarantee that the integrity of this communication has been maintained and nor is this communication free of viruses, interceptions or interference.

----- Original Message -----
From: Steve Urosevich
To: Chris Harris
Cc: steveurosevich@yahoo.com

Williams, Bettyjo

From: dmeister@wernervas.com
Sent: Wednesday, July 20, 2011 2:04 PM
To: Urosevich, Steve
Cc: jthede@wernervas.com
Subject: Re: 236 Information
Attachments: 236form.pdf; Chris Harris Email.pdf

Thanks Steve.

I noticed the email from Chris Harris states he is working on getting FedEx or another air carrier to provide the transportation.

I thought you said Werner Global Logistics would handle the transportation.

I have added Jay Thede from our Air/Expedited group to assist with any air transportation questions.

I will review the 236 form and get back to you as soon as possible.



Debbie Meister
Licensed U.S. Customs Broker
14507 Frontier Road Omaha NE 68138
Tel: 1-800-431-7523 or 402-895-6640 x 4495
Mobile: 402-779-6760 Fax: 402-894-3760

From: "Urosevich, Steve" <steve.urosevich@nebraska.gov>
To: "dmeister@wernervas.com" <dmeister@wernervas.com>
Cc: "Urosevich, Steve" <steve.urosevich@nebraska.gov>
Date: 07/20/2011 01:56 PM
Subject: 236 Information

Hello Debbie,

Per our phone conversation, please find attached the 263 and additional information from the consignor.

Our contact info is as follows:

Steve L. Urosevich
Chief Operating Officer, Health Services
Nebraska Department of Corrections
steve.urosevich@nebraska.gov
Ofc. 402-479-5630
Cell. 402-214-1156
Fax. 402-479-5679

Patrick Werner
Administrative Assistant II, Health Services
Nebraska Department of Corrections
402-479-5703

Thanks and have a great day!

Williams, Bettyjo

From: dmeister@wernervas.com
Sent: Thursday, July 21, 2011 9:46 AM
To: Urosevich, Steve
Subject: Re: 236 Information
Attachments: 236form.pdf; Chris Harris Email.pdf; WGL POA and Terms April 2010.pdf

Steve,

We need a signed power of attorney in order to clear Customs. It must be signed by an officer of the organization and per US regulations, I must have the original returned to me.

I spoke to Jay in our air department and he advises the 236 should be signed by the importer.

I am going to contact our local Customs director and let you know what else we need to do before this ships.



Debbie Meister
Licensed U.S. Customs Broker
14507 Frontier Road Omaha NE 68138
Tel: 1-800-431-7523 or 402-895-6640 x 4495
Mobile: 402-779-6760 Fax: 402-894-3760

From: "Urosevich, Steve" <steve.urosevich@nebraska.gov>
To: "dmeister@wernervas.com" <dmeister@wernervas.com>
Cc: "Urosevich, Steve" <steve.urosevich@nebraska.gov>
Date: 07/20/2011 01:56 PM
Subject: 236 Information

Hello Debbie,

Per our phone conversation, please find attached the 263 and additional information from the consignor.

Our contact info is as follows:

Steve L. Urosevich
Chief Operating Officer, Health Services
Nebraska Department of Corrections
steve.urosevich@nebraska.gov
Ofc. 402-479-5630
Cell. 402-214-1156
Fax. 402-479-5679

Patrick Werner
Administrative Assistant II, Health Services
Nebraska Department of Corrections
402-479-5703

Thanks and have a great day!

Patrick

Williams, Bettyjo

From: Urosevich, Steve
Sent: Thursday, September 22, 2011 11:29 AM
To: chrisharris@harrispharmallp.com
Subject: RE: Information

Thank you Chris

From: chrisharris@harrispharmallp.com [mailto:chrisharris@harrispharmallp.com]
Sent: Thursday, September 22, 2011 11:07 AM
To: Urosevich, Steve
Subject: Re: Information

The coa of testing is what the fda will pass during shipment. Also product is as per bristish pharmacopia so by this quality is fantastic. Out of office will sent you the COA of the testing tomorrow

Sent on my BlackBerry® from Vodafone

From: "Urosevich, Steve" <steve.urosevich@nebraska.gov>
Date: Thu, 22 Sep 2011 10:43:14 -0500
To: Chris Harris<chrisharris@harrispharmallp.com>
Subject: RE: Information

Thank you Chris, please forward the documentation from the India FDA that our drug has been cleared for shipment, thank you.

From: Chris Harris [mailto:chrisharris@harrispharmallp.com]
Sent: Thursday, September 22, 2011 7:12 AM
To: Urosevich, Steve
Subject: Re: Information

Hi Steve,

Just sending you the pics of the product which has come back along with the package insert.

Regards,
Chris Harris
CEO
Harris Pharma LLP.
145 B Bosepukur Road,
Prashanti Building,
Kolkata 700039
West Bengal,
India
Phone (Direct): +(91)-33-40614353
Cell: +(91)-9836827779
www.harrispharmallp.com

DISCLAIMER:

Information contained and transmitted by this E-MAIL including any attachment is proprietary to Harris Pharma LLP and is intended solely for the addressee/s, and may contain information that is privileged, confidential or exempt from disclosure under applicable law. Access to this e-mail and/or to the attachment by anyone else is unauthorized. If this is a forwarded message, the content and the views expressed in this E-MAIL may not reflect those of the Company. If you are not the intended recipient, an agent of the intended recipient or a person responsible for delivering the information to the named recipient, you are notified that any use, distribution, transmission, printing, copying or dissemination of this information in any way or in any manner is strictly prohibited. If you are not the intended recipient of this mail kindly delete from your system and inform the sender. There is no guarantee that the integrity of this communication has been maintained and nor is this communication free of viruses, interceptions or interference.

From: Urosevich, Steve
Sent: Tuesday, September 20, 2011 7:04 PM
To: chrisharris@harrispharmallp.com
Subject: RE: Information

Thank you Chris

From: chrisharris@harrispharmallp.com [mailto:chrisharris@harrispharmallp.com]
Sent: Tuesday, September 20, 2011 8:04 AM
To: Urosevich, Steve
Subject: Re: Information

Will get all tomorrow when stock arrives at my office. Yes with the product the product inserts will be there. Will also take a pic of the stock when it arrives and send you.

Sent on my BlackBerry® from Vodafone

From: "Urosevich, Steve" <steve.urosevich@nebraska.gov>
Date: Tue, 20 Sep 2011 07:52:44 -0500
To: Chris Harris<chrisharris@harrispharmallp.com>
Subject: Information

Please forward me the documents that cleared our product, also we need to make sure product insert information is included with the shipment, thanks

Steve L. Urosevich
Chief Operating Officer, Health Services
Nebraska Department of Corrections
steve.urosevich@nebraska.gov
Ofc. 402-479-5630
Cell. 402-214-1156
Fax. 402-479-5679

Williams, Bettyjo

From: Chris Harris <chrisharris@harrispharmallp.com>
Sent: Saturday, October 01, 2011 5:52 AM
To: Urosevich, Steve
Subject: Re: check
Attachments: COA ANES.pdf, COA DAFFOTAL.pdf

Hi Steve,

Pls find attached the COA of the Sodium Thiopental. I am Still in office waiting for the pickup by FEDEX.

Regards,
Chris Harris
CEO
Harris Pharma LLP.
145 B Bosepukur Road,
Prashanti Building,
Kolkata 700039
West Bengal,
India
Phone (Direct): +(91)-33-40614353
Cell: +(91)-9836827779
www.harrispharmallp.com

DISCLAIMER:

Information contained and transmitted by this E-MAIL including any attachment is proprietary to Harris Pharma LLP and is intended solely for the addressee/s, and may contain information that is privileged, confidential or exempt from disclosure under applicable law. Access to this e-mail and/or to the attachment by anyone else is unauthorized. If this is a forwarded message, the content and the views expressed in this E-MAIL may not reflect those of the Company. If you are not the intended recipient, an agent of the intended recipient or a person responsible for delivering the information to the named recipient, you are notified that any use, distribution, transmission, printing, copying or dissemination of this information in any way or in any manner is strictly prohibited. If you are not the intended recipient of this mail kindly delete from your system and inform the sender. There is no guarantee that the integrity of this communication has been maintained and nor is this communication free of viruses, interceptions or interference.

From: Urosevich, Steve
Sent: Friday, September 23, 2011 7:43 PM
To: chrisharris@harrispharmallp.com
Subject: check

Did you receive the check?

Steve L. Urosevich
Chief Operating Officer, Health Services
Nebraska Department of Corrections
steve.urosevich@nebraska.gov
Ofc. 402-479-5630

FINISHED PRODUCT CERTIFICATE OF ANALYSIS			
PRODUCT		ANES 1.0 INJECTION THIOPENTAL SODIUM FOR INJECTION BP	MFG. DATE : Dec-10
BATCH NO.		DGX039	EXPIRY DATE : May-13
BATCH SIZE		2500 Vials	DATE OF RECEIPT : 09-12-10
SAMPLE QTY		30 x 1.0 gm.	DATE OF REPORT : 23-12-10
RESULT OF ANALYSIS			
S. No	TEST PERFORMED	STD. SPECIFICATION	RESULT
1.	DESCRIPTION	Yellowish white hygroscopic powder filled 1 gm in 30 ml colorless vials with blue colored flip off aluminium seal.	Yellowish white hygroscopic powder filled 1 gm in 30 ml colorless vials with blue colored flip off aluminium seal.
2.	IDENTIFICATION		
a.	IR SPECTRA	The infrared absorption spectrum of the residue is concordant with the reference spectrum of thiopental.	The infrared absorption spectrum of the residue is concordant with the reference spectrum of thiopental.
b.	NON-NITROGEN SUBSTITUTED BARBITURATES	Gives the reaction for non-nitrogen substituted barbiturates	Gives the reaction for non-nitrogen substituted barbiturates
c.	TEST FOR SODIUM SALTS	Gives the reaction for sodium salts	Gives the reaction for sodium salts
3.	CLARITY & COLOUR OF SOLUTION	10% w/v solution in carbon dioxide free water is clear and not more intensely coloured than reference solution GY ₂	10% w/v solution in carbon dioxide free water is clear and not more intensely coloured than reference solution GY ₂
4.	RELATED SUBSTANCES (TLC)	Any spot in the chromatogram with the test solution (1), apart from the principal spot, is not more intense than the spot in chromatogram obtained with the reference solution (0.5%).	No spot is more intense than the spot in chromatogram obtained with the reference solution (0.5%).
5.	LOSS ON DRYING	Not more than 2.5%	1.1% w/w
6.	pH*	Between 10.2 to 11.2 of solution (0.8gm in 10ml) of Carbon Dioxide free water)	10.86
7.	STERILITY TEST	Passes the sterility test by membrane filtration method.	Passes the sterility test by membrane filtration method.
8.	BACTERIAL ENDOTOXINS TEST*	Not more than 1.0 USP Endotoxins Unit per mg of Thiopental Sodium.	Less than 1.0 USP Endotoxins Unit per mg of Thiopental Sodium.
9.	UNIFORMITY OF WEIGHT	±10.0%.	Min. 1022.7 mg (-1.25%) Max. 1065.4 mg (+2.88%)
10.	AVG. FILL CHECKED AND FOUND	Claim: 1 gm / vial.	1035.6 mg / Vial.
11.	ASSAY		
	THIOPENTAL CONTENT	Not less than 77% and Not more than 92%	89.28%
	SODIUM CONTENT	Not less than 9.4% and Not more than 11.3%	11.2%


REPORT: In the opinion of the undersigned given sample complies as per standard specifications.

*Additional Tests

Analyst

Checked by

Manager-Quality Assurance



SWITZERLAND : Hebestrasse 134, CH-4104, Oberwil Tel.: +41 614051000 Fax : +41 614051019 www.naari.ch
INDIA : C-82, Hostery Complex, Phase-II, Noida-201 305, U.P. Tel.: +91 126 4070760 Fax : +91 126 4070715

FINISHED PRODUCT CERTIFICATE OF ANALYSIS			
PRODUCT NAME : Dafforal (Thiopental Sodium for Injection B.P)			
BATCH NO : JG1003	REC. DATE : 12-07-11	www.naari.in +91 614051019 +91 614051006 +91 120 4070700 +91 120 4070715	
MFG. DATE : 07-11	EXP. DATE : 12-13		
BATCH SIZE : 51.830 Vials	REPORT DATE : 18-07-11		
SAMPLE QTY. : 25 Vials	A.R. NO. : SP50711027		
TEST	OBSERVATION	SPECIFICATION	
Description	Yellowish white hygroscopic powder filled 1gm in 30ml colourless vials with blue coloured flip off aluminium seal	Yellowish white hygroscopic powder filled 1gm in 30ml colourless vials with blue coloured flip off aluminium seal	
Identification a. (By IR)	The infrared absorption spectrum of the residue is concordant with the reference spectrum of thiopental.	The infrared absorption spectrum of the residue is concordant with the reference spectrum of thiopental.	
b. Non - Nitrogen Substituted Barbiturates	Gives the reaction for non-nitrogen substitutes.	Gives the reaction for non-nitrogen substituted barbiturates.	
c. Test for Sodium Salts	Gives the reaction for sodium salts.	Gives the reaction for sodium salts.	
Clarity and colour of solution	10% w/v solution in carbon dioxide free water is clear and not more intensely coloured than reference solution (Y).	10% w/v solution in carbon dioxide free water is clear and not more intensely coloured than reference solution (Y).	
Related substances (TLC)	Any spot in the chromatogram with the test solution (1), apart from the principal spot, is not more intense than the spot in chromatogram obtained with the reference solution (0.5%).	No spot is more intense than the spot in chromatogram obtained with the reference solution (0.5%).	
Loss on Drying	2.21% w/w	NMT 2.5% w/w	
pH*	10.86	Between 10.2 to 11.2 of solution (0.8 in 10ml of Carbon Dioxide free water)	
*Sterility Test	Passes the sterility test by membrane filtration method.	Passes the sterility test by membrane filtration method.	
Uniformity of Weights	Min: 1049.3 mg Max: 1078.6 mg 1058.6 mg	(1007.0 - 1113.0) mg (1038.8 - 1181.2) mg	
Avg. fill checked and found			
Assay:	Obtained	Claim	Limit
Each Vial Contains:			
Thiopental Sodium B.P.	999.20 mg	1000 mg	(900-1100) mg
Thiopentone	89.12%	---	Not less than 77.0% and not more than 92.0%
Sodium	10.8%	---	Not less than 9.4% and not more than 11.8%
Report : In the opinion of the undersigned given sample complies as per standard specification			

* NOTE: - Sterility of this batch incubated on 04-07-11.

* Additional Tests



Analyst



Checked by



Manager Quality Control

MEDTOX LABORATORIES INC.
402 WEST COUNTY ROAD D
ST. PAUL, MN 55112
651-636-7466

Jennifer A. Collins, Ph.D.
Dr Mark Catlin, M.D.
Karla Walker, Pharm.D.
PAGE 1

COMPUTER-GENERATED FACSIMILE LABORATORY REPORT

NEBRASKA STATE PATROL HQ DIVISION 1233 ARAPAHOE LINCOLN, NE 68502	PATIENT NAME ID, M2474794	Social Security
	PATIENT I.D. NO. M2474794	AGE SEX SPECIMEN F3776675
	DOB:	
	DATE TIME	DATE DATE
	COLLECTED COLLECTED	RECEIVED REPORTED
	NOT GIVEN	2:20PM 10/26/2011 10/27/2011
TEST(S) REQUESTED	RESULTS	UNITS REFERENCE RANGE

UNKNOWN VIAL CONTENTS ANALYSIS

VIAL ANALYSIS

IDENTIFIED DRUG(S): THIOPENTAL ++POSITIVE++

PENTOBARBITAL

ANALYSIS PERFORMED ON WHITE/YELLOW POWDER.

The drugs screened for in this unknown specimen include:
acetaminophen, acetone, acetylmorphine, alprazolam, amantadine,
amitriptyline, amobarbital, amoxapine, amphetamine, antidepressants,
antipsychotics, barbiturates, benzodiazepines, benzotropine,
brompheniramine, bupropion, butabarbital, butalbital, caffeine,
carbamazepine, carisoprodol, chlordiazepoxide, chlorpheniramine,
chlorpromazine, chlorzoxazone, clomipramine, clonazepam, clozapine,
cocaine, codeine, cyclobenzaprine, desalkylflurazepam, desipramine,
desmethyldiazepam, dextromethorphan (as methorphan), diazepam,
dihydrocodeine, diltiazem, diphenhydramine, doxepin, doxylamine,
ephedrine, ethosuximide, ethyl alcohol, fentanyl, fluoxetine,
fluphenazine, flurazepam and metabolite, fluvoxamine, glutethimide,
guaifenesin, halazepam, haloperidol, heroin, hydrocodone,
hydromorphone, hydroxyzine, ibuprofen, imipramine, isopropyl alcohol,
ketoprofen, lidocaine, lorazepam, loxapine, maprotiline, marijuana
(THC), mefenamic acid, meperidine, mephobarbital, mepivacaine, MDA,
MDMA, meprobamate, mesoridazine, methadone, methamphetamine,
methapyrilene, methaqualone, methocarbamol, methorphan, methyl
alcohol, methylphenidate, methyprylon, metoprolol, midazolam,
morphine, naproxen, nifedipine, nortriptyline, opiates, orphenadrine,
oxaprozin, oxazepam, oxycodone, paroxetine, pentazocine,
pentobarbital, perphenazine, phenacetin, phenacyclidine, phenmetrazine,
phenobarbital, phentermine, phenylpropanolamine, phenytoin, primidone,
procainamide, procaine, prochlorperazine, promazine, promethazine,
propoxyphene, propranolol, protriptyline, pseudoephedrine, pyrilamine,
salicylate, secobarbital, sertraline, temazepam, THC (marijuana),
theophylline, thiopental, thioridazine, tolmetin, tramadol, trazodone,
triazolam, trifluoperazine, trihexyphenidyl, trimipramine,
tripelennamine, valproic acid, venlafaxine, and verapamil.
This list is not necessarily inclusive of all possible drugs that
could be identified.

*** FINAL REPORT ***

MEDTOX LABORATORIES FAX Server Reported: 1 Specimens on 10/27/2011 2:20 PM
F3776675

Your autofax group is: RM403635

Please refer to this group when calling for assistance

End of report

UPS is now the MEDTOX carrier of choice. The most efficient method of receiving
UPS airbills is to print them directly at <http://medtox.upsrow.com>
If you do not have internet access and need airbills and shipping bags sent
to you, please call our Collection Site Coordination Team at 888-310-2911.
FAQ's regarding the UPS transition can be found at www.medtox.com

Nebraska Chief Deputy AG Cookson contacts with USDOJ

Subject: Re: contact info

Date: Wednesday, April 27, 2011 5:51:25 PM CT

From: Cookson, David

To: Wilkinson, Monty (OAG)

Thanks Monty

David D. Cookson
Chief Deputy Attorney General
State of Nebraska
Cell (402) 430-4219
Sent from my iPhone

On Apr 27, 2011, at 5:41 PM, "Wilkinson, Monty (OAG)" <Monty.Wilkinson@usdoj.gov> wrote:

David-

My colleague in the Deputy Attorney General's Office is Deborah Johnston. Her number is 202-305-3481. She is expecting your call.

Will be on touch on the meeting issue.

Monty

Monty Wilkinson
Deputy Chief of Staff and Counselor to the Attorney General
950 Pennsylvania Avenue, NW, Rm. 5112
Washington, DC 20530
(202) 514-9798 (office)
(202) 305-5289 (mobile)

Subject: RE: Meeting w/DOJ and DEA
Date: Thursday, April 28, 2011 2:59:12 PM CT
From: Johnston, Deborah A. (ODAG)
To: Cookson, David

No problem. The other email is my United States Attorney's Office email. I am here on a detail so I have two email addresses.

Looking forward to meeting with you next week.

Debbie

From: Cookson, David [mailto:david.cookson@nebraska.gov]
Sent: Thursday, April 28, 2011 3:55 PM
To: Johnston, Deborah A. (ODAG)
Subject: FW: Meeting w/DOJ and DEA

Debbie –

I apologize. I apparently sent the email below to an old email address.

Thanks again and I look forward to meeting you next week.

Dave

David D. Cookson
Chief Deputy Attorney General
State of Nebraska
(402) 471-3812 office
(402) 430-4219 cell

Please note new email address david.cookson@nebraska.gov

From: Cookson, David
Sent: Thursday, April 28, 2011 2:52 PM
To: deborah.johnston@usdoj.gov
Cc: monty.wilkinson@usdoj.gov
Subject: Meeting w/DOJ and DEA

Debbie –

Thanks again for setting up the meeting with your office, DEA and myself for Friday May 6, 2011 at 9:30 am at Main Justice. Let me know the room number when you get that information. This will also confirm that the State of Nebraska will hold off filing any litigation related to the issue of lethal injection drugs and DEA will wait to proceed with any attempts to seize or obtain those same drugs from Nebraska until we have had a chance to meet and see if we can work through these issues.

Thanks again to you and Monty for your cooperation in setting up this meeting.

Dave

Subject: Meeting with Deborah Johnston

Date: Monday, May 2, 2011 12:09:50 PM CT

From: Cardwell, Christine (SMO)

To: Cookson, David

CC: Johnston, Deborah A. (ODAG)

David,

A meeting will convene on Friday, May 6, 2011 at 9:30am with Deborah Johnston and others. We are located at Main Justice (on Constitution Avenue., between 9th and 10th Streets, N.W., Washington DC 20530. I will send our security desk your name prior to your arrival. If you have any questions, please contact Christine Cardwell at (202) 514-2674. Thank you

Christine E. Cardwell
Staff Assistant
Office of the Deputy Attorney General
Washington, DC 20530
phone: (202) 514-2674
fax (202) 616-1239

Subject: Re: Importer list

Date: Thursday, May 12, 2011 8:49:43 AM CT

From: Rannazzisi, Joseph T.

To: Cookson, David

Will get an expanded list...

----- Original Message -----

From: Cookson, David [<mailto:david.cookson@nebraska.gov>]

Sent: Thursday, May 12, 2011 09:20 AM

To: Rannazzisi, Joseph T.

Subject: Re: Importer list

Thanks Joe. Our people have informed me that none of these entities are willing to act as an importer. Would it be possible to access a broader list of DEA licensed importers?

Thanks, Dave

David D. Cookson
Chief Deputy Attorney General
State of Nebraska
Cell (402) 430-4219
Sent from my iPhone

On May 10, 2011, at 7:53 PM, "Rannazzisi, Joseph T." <Joseph.T.Rannazzisi@usdoj.gov> wrote:

Mr. Cookson,

Good evening. It was great meeting you last week. I have provided the following importers per your request...

Danisco USA Kansas

KV Pharmaceutical Company Missouri

Mallinckrodt inc Missouri

Meridian Medical Tech Missouri

Sigma Aldrich Manufacturing Missouri

Tocris Cookson Missouri

R.T. Corp. Wyoming

Hope this helps....

Joe Rannazzisi

-----Original Message-----

From: Cookson, David [<mailto:david.cookson@nebraska.gov>]

Sent: Monday, May 09, 2011 12:02 PM

To: Rannazzisi, Joseph T.

Cc: wendy.h.goggin@usdoj.com; Gleason, Robert (Chris); Deborah A. Johnston

Subject: Importer list

Mr. Rannazzisi

It was a pleasure meeting with you Friday. I am following up on your offer to provide the State of Nebraska with a list of approved drug importers should we locate an alternate source of sodium thiopental. If there is somewhere that you could point us to look, we would be happy to do so.

Again, I appreciate your assistance.

Thanks, Dave
David D. Cookson
Chief Deputy Attorney General
State of Nebraska
Cell (402) 430-4219
Sent from my iPhone

Subject: Importer List

Date: Thursday, May 12, 2011 10:33:59 AM CT

From: Gallagher, Cathy A.

To: Cookson, David

CC: Rannazzisi, Joseph T.

David,

It was nice speaking with you. Attached is a list with all DEA importers registered in schedule 3N.

<<Importers.xlsx>>

Please do not hesitate to reach out if you have any questions.

Thanks,

Cathy Gallagher

Acting Chief

Liaison and Policy Section

Office of Diversion Control

Cell: 202-373-8643

Ofc: 202-307-7283

Subject: RE: Update

Date: Monday, May 23, 2011 11:09:23 AM CT

From: Johnston, Deborah A. (ODAG)

To: Cookson, David, Rannazzisi, Joseph T. (DEA-US)

CC: Goggin, Wendy H. (DEA-US)

That's fine. I have a meeting at 3 but its right down the hall.

Debbie

PS the above is Wendy's correct email address.

-----Original Message-----

From: Cookson, David [<mailto:david.cookson@nebraska.gov>]

Sent: Monday, May 23, 2011 12:06 PM

To: Rannazzisi, Joseph T. (DEA-US)

Cc: Johnston, Deborah A. (ODAG); wendy.h.goggin@usdoj.com

Subject: Re: Update

Let's say 2:30 ET. I will send around a call in number.

David D. Cookson
Chief Deputy Attorney General
State of Nebraska
Cell (402) 430-4219
Sent from my iPhone

On May 23, 2011, at 11:04 AM, "Rannazzisi, Joseph T." <Joseph.T.Rannazzisi@usdoj.gov> wrote:

Those times are ok with me.

----- Original Message -----

From: Johnston, Deborah A. (ODAG) [<mailto:Deborah.A.Johnston@usdoj.gov>]

Sent: Monday, May 23, 2011 11:29 AM

To: 'Cookson, David' <david.cookson@nebraska.gov>; Rannazzisi, Joseph T.; wendy.h.goggin@usdoj.com

<wendy.h.goggin@usdoj.com>

Subject: RE: Update

I'm available between 2 and 3 or after 5:15 eastern time.

Debbie

-----Original Message-----

From: Cookson, David [<mailto:david.cookson@nebraska.gov>]

Sent: Monday, May 23, 2011 11:28 AM

To: Rannazzisi, Joseph T. (DEA-US); wendy.h.goggin@usdoj.com

Cc: Johnston, Deborah A. (ODAG)

Subject: Update

Do you have time for a short call today so that we can provide you an update on the status of the steps we discussed?

David D. Cookson
Chief Deputy Attorney General
State of Nebraska
Cell (402) 430-4219

 Sent from my iPhone

Subject: Re: Update

Date: Monday, May 23, 2011 11:04:21 AM CT

From: Rannazzisi, Joseph T.

To: Deborah.A.Johnston@usdoj.gov, Cookson, David, wendy.h.goggin@usdoj.com

Those times are ok with me.

—— Original Message ——

From: Johnston, Deborah A. (ODAG) [<mailto:Deborah.A.Johnston@usdoj.gov>]

Sent: Monday, May 23, 2011 11:29 AM

To: 'Cookson, David' <david.cookson@nebraska.gov>; Rannazzisi, Joseph T.; wendy.h.goggin@usdoj.com

<wendy.h.goggin@usdoj.com>

Subject: RE: Update

I'm available between 2 and 3 or after 5:15 eastern time.

Debbie

—— Original Message ——

From: Cookson, David [<mailto:david.cookson@nebraska.gov>]

Sent: Monday, May 23, 2011 11:28 AM

To: Rannazzisi, Joseph T. (DEA-US); wendy.h.goggin@usdoj.com

Cc: Johnston, Deborah A. (ODAG)

Subject: Update

Do you have time for a short call today so that we can provide you an update on the status of the steps we discussed?

David D. Cookson
Chief Deputy Attorney General
State of Nebraska
Cell (402) 430-4219
Sent from my iPhone

NEBRASKA STATE PENITENTIARY
4201 14TH SOUTH STREET
LINCOLN, NE 68502-0000-000



DEA REGISTRATION NUMBER	THIS REGISTRATION EXPIRES	FEE PAID
RN0414184	10-31-2011	FEE EXEMPT
SCHEDULES	BUSINESS ACTIVITY	ISSUE DATE
3N,	IMPORTER	05-25-2011
NEBRASKA STATE PENITENTIARY 4201 14TH SOUTH STREET LINCOLN, NE 68502-0000		

CONTROLLED SUBSTANCE REGISTRATION CERTIFICATE
UNITED STATES DEPARTMENT OF JUSTICE
DRUG ENFORCEMENT ADMINISTRATION
WASHINGTON D.C. 20537

This registration is only for use at Federal or State institutions.

Sections 304 and 1008 (21 USC 824 and 958) of the Controlled Substances Act of 1970, as amended, provide that the Attorney General may revoke or suspend a registration to manufacture, distribute, dispense, import or export a controlled substance.

THIS CERTIFICATE IS NOT TRANSFERABLE ON CHANGE OF OWNERSHIP, CONTROL, LOCATION, OR BUSINESS ACTIVITY, AND IT IS NOT VALID AFTER THE EXPIRATION DATE.

CONTROLLED SUBSTANCE REGISTRATION CERTIFICATE
UNITED STATES DEPARTMENT OF JUSTICE
DRUG ENFORCEMENT ADMINISTRATION
WASHINGTON D.C. 20537

DEA REGISTRATION NUMBER	THIS REGISTRATION EXPIRES	FEE PAID
RN0414184	10-31-2011	FEE EXEMPT
SCHEDULES	BUSINESS ACTIVITY	ISSUE DATE
3N,	IMPORTER	05-25-2011
NEBRASKA STATE PENITENTIARY 4201 14TH SOUTH STREET LINCOLN, NE 68502-0000		

This registration is only
for use at Federal or
State institutions.

Sections 304 and 1008 (21 USC 824 and 958) of the Controlled Substances Act of 1970, as amended, provide that the Attorney General may revoke or suspend a registration to manufacture, distribute, dispense, import or export a controlled substance.

THIS CERTIFICATE IS NOT TRANSFERABLE ON CHANGE OF OWNERSHIP, CONTROL, LOCATION, OR BUSINESS ACTIVITY, AND IT IS NOT VALID AFTER THE EXPIRATION DATE.

NEW - Page 1

C. Listed below are examples of drug codes for schedules 1-5. Check all drug codes you handle as required.
 SCHEDULE For more information, see our web site at www.deadiversion.usdoj.gov, 21 CFR 1308, or call 1-800-882-9539

ANALYTICAL LAB.....not required to list drug codes	DISTRIBUTOR.....must mark all schedule 1 &/or 2012 drug codes
RESEARCHER W/SCHED 1.....must list sched 1 drug codes	REVERSE DISTRIBUTOR.....must mark all schedule 1 &/or 2012 drug codes
RESEARCHER W/SCHED 2-5.....must list sched 2 drug codes	MANUFACTURER.....must mark all schedule 1&2 drug codes
to be manufactured or imported as part of research	EXPORTER OR IMPORTER.....must mark all schedule 1-5 drug codes
CANINE HANDLER.....may handle sched 1-5; must list sched 1 drug codes	

If you bulk manufacture a substance, check the 'BULK?' column after the applicable class code.

SCHEDULE 1 NARCOTIC & NON-NARCOTIC	CODE	BULK?	SCHEDULE 2 NARCOTIC & NON-NARCOTIC	CODE	BULK?
<input type="checkbox"/> 3,4-Methylenedioxymphetamine (MDA)	7400	_____	<input checked="" type="checkbox"/> Amobarbital (Amytal, Tuinal)	2125	_____
<input type="checkbox"/> 3,4-Methylenedioxymethamphetamine (MDMA)	7405	_____	<input checked="" type="checkbox"/> Amphetamine (Dexedrine, Adderall)	1100	_____
<input type="checkbox"/> 4-Methyl-2,5-Dimethoxyamphetamine (DOM, STP)	7395	_____	<input checked="" type="checkbox"/> Cocaine (Methyl benzoylcegonine)	9041	_____
<input type="checkbox"/> 4-Methylaminorex -cis isomer (U4Euh, McN-422)	1590	_____	<input checked="" type="checkbox"/> Codeine (Morphine methyl ester)	9050	_____
<input type="checkbox"/> Alphacetylmethadol (except LAAM)	9603	_____	<input checked="" type="checkbox"/> Dextropropoxyphene (bulk)	9273	_____
<input type="checkbox"/> Bufotenine (Mappine)	7433	_____	<input checked="" type="checkbox"/> Diphenoxylate	9170	_____
<input type="checkbox"/> Cannabidiol (Marijuana)	7360/7372	_____	<input checked="" type="checkbox"/> Diprenorphine (M50-50)	9058	_____
<input type="checkbox"/> Diethyltryptamine (DET)	7434	_____	<input checked="" type="checkbox"/> Ethylmorphine (Dionin)	9190	_____
<input type="checkbox"/> Difenoixin 1MG/25UG A(SO4 /DLI (Motofen)	9187	_____	<input checked="" type="checkbox"/> Etorphine Hydrochloride (M89)	9059	_____
<input type="checkbox"/> Dimethyltryptamine (DMT)	7435	_____	<input checked="" type="checkbox"/> Fentanyl (Duragesic)	9801	_____
<input type="checkbox"/> Etorphine (except HCL)	9056	_____	<input checked="" type="checkbox"/> Hydrocodone (Dihydrocodeinone)	9193	_____
<input type="checkbox"/> Gamma Hydroxybutyric Acid (GHB)	2010	_____	<input checked="" type="checkbox"/> Hydromorphone (Dilaudid)	9150	_____
<input type="checkbox"/> Heroin (Diamorphine)	9200	_____	<input checked="" type="checkbox"/> Levo-Alphacetylmethadol (LAAM)	9648	_____
<input type="checkbox"/> Ibogaine	7260	_____	<input checked="" type="checkbox"/> Levorphanol (Levo-Dromoran)	9220	_____
<input type="checkbox"/> Lysergic Acid Diethylamide (LSD)	7315	_____	<input checked="" type="checkbox"/> Meperidine (Demerol, Mepergan)	9230	_____
<input type="checkbox"/> Mescaline	7381	_____	<input checked="" type="checkbox"/> Methadone (Dolophine, Methadose)	9250	_____
<input type="checkbox"/> Marijuana	7360	_____	<input checked="" type="checkbox"/> Methamphetamine (Desoxyn)	1105	_____
<input type="checkbox"/> Methaqualone (Quaalude)	2565	_____	<input checked="" type="checkbox"/> Methylphenidate (Concerta, Ritalin)	1724	_____
<input type="checkbox"/> Normorphine	9313	_____	<input checked="" type="checkbox"/> Morphine (MS Contin, Roxanol)	9300	_____
<input type="checkbox"/> Psycote	7415	_____	<input checked="" type="checkbox"/> Opium powdered	9639	_____
<input type="checkbox"/> Psilocybin	7437	_____	<input checked="" type="checkbox"/> Opium raw	9600	_____
<input type="checkbox"/> Tetrahydrocannabinols (THC)	7370	_____	<input checked="" type="checkbox"/> Oxycodone (Oxycontin, Percocet)	9143	_____
SCHEDULE 3 NARCOTIC & NON-NARCOTIC	CODE	BULK?	<input checked="" type="checkbox"/> Oxymorphone (Numorphan)	9652	_____
<input checked="" type="checkbox"/> Anabolic Steroids	4000	_____	<input checked="" type="checkbox"/> Pentobarbital (Nembutal)	2270	_____
<input checked="" type="checkbox"/> Barbituric acid derivative	2100	_____	<input checked="" type="checkbox"/> Phencyclidine	7471	_____
<input checked="" type="checkbox"/> Benzphetamine (Didrex, Inapetyl)	1228	_____	<input checked="" type="checkbox"/> Secobarbital (Seconal, Tuinal)	2315	_____
<input checked="" type="checkbox"/> Buprenorphine (Buprenex, Temgesic)	9064	_____	<input checked="" type="checkbox"/> Thebaine	9333	_____
<input checked="" type="checkbox"/> Butabarbital	2100/2175	_____	SCHEDULE 4 NARCOTIC & NON-NARCOTIC	CODE	BULK?
<input checked="" type="checkbox"/> Butalbital	2100/2165	_____	<input checked="" type="checkbox"/> Alprazolam (Xanax)	2882	_____
<input checked="" type="checkbox"/> Codeine combo product (Empirin)	9804	_____	<input checked="" type="checkbox"/> Barbital (Veronal, Plexoral)	2145	_____
<input checked="" type="checkbox"/> Dihydrocodeine combo product (Compal)	9807	_____	<input checked="" type="checkbox"/> Chloral Hydrate (Noctec)	2466	_____
<input checked="" type="checkbox"/> Dronabinol in sesame oil soft cap (Marinol)	7369	_____	<input checked="" type="checkbox"/> Chlordiazepoxide (Librium)	2744	_____
<input checked="" type="checkbox"/> Gamma Hydroxybutyric Acid preparations (Zyrem)	2012	_____	<input checked="" type="checkbox"/> Clonazepam (Klonopin)	2737	_____
<input checked="" type="checkbox"/> Hydrocodone combo product (Lorcet, Vicodin)	9806	_____	<input checked="" type="checkbox"/> Clorazepate (Fronxene)	2768	_____
<input checked="" type="checkbox"/> Ketamine (Ketaset, Ketalar)	7285	_____	<input checked="" type="checkbox"/> Diazepam (Vallium)	2765	_____
<input checked="" type="checkbox"/> Morphine combo product	9810	_____	<input checked="" type="checkbox"/> Flurazepam (Dalmene)	2767	_____
<input checked="" type="checkbox"/> Nalorphine (Nalline)	9400	_____	<input checked="" type="checkbox"/> Lorazepam (Ativan)	2865	_____
<input checked="" type="checkbox"/> Opium combo product (Paregoric)	9809	_____	<input checked="" type="checkbox"/> Meprobamate (Miltown, Equanil)	2820	_____
<input checked="" type="checkbox"/> Pentobarbital suppository dosage (FP3)	2270	_____	<input checked="" type="checkbox"/> Midazolam (Versed)	2884	_____
<input checked="" type="checkbox"/> Phendimetrazine (Plegine, Bontril)	1815	_____	<input checked="" type="checkbox"/> Oxazepam (Serax, Serenid-D)	2835	_____
<input checked="" type="checkbox"/> Thiopental	2100/2329	_____	<input checked="" type="checkbox"/> Phenobarbital (Luminal)	2285	_____
SCHEDULE 5 NARCOTIC & NON-NARCOTIC	CODE	BULK?	<input checked="" type="checkbox"/> Phenetermine (Fastin, Zantril)	1640	_____
<input checked="" type="checkbox"/> Codeine preparations (Robitussin A-C, Pedicof)	9050	_____	<input checked="" type="checkbox"/> Temazepam (Restoril)	2925	_____
<input checked="" type="checkbox"/> Pyrovalerone (Centraton, Thymergix)	1485	_____	<input checked="" type="checkbox"/> Zolpidem (Ambien, Stilnox)	2783	_____

WRITE IN ADDITIONAL CODES You may write in additional drug codes in this section. Attach a separate sheet if needed.

SECTION 4**STATE LICENSE(S)**

Be sure to include both state license numbers if applicable

State License Number (required)

2572

Expiration Date (required) 07.01.2011
MM-DD-YYYYWhat state was this license issued in? Nebraska

State Controlled Substance License Number (if required)

Expiration Date / /
MM-DD-YYYY

What state was this license issued in? _____

SECTION 5**LIABILITY**

1. Has the applicant ever been convicted of a crime in connection with controlled substance(s) under state or federal law, or is any such action pending? YES NO
-
- ☐
- ☒

Date(s) of incident MM-DD-YYYY: ☐-☐-☐**IMPORTANT**

All questions in this section must be answered.

2. Has the applicant ever surrendered (for cause) or had a federal controlled substance registration revoked, suspended, restricted, or denied, or is any such action pending? YES NO
-
- ☐
- ☒

Date(s) of incident MM-DD-YYYY: ☐-☐-☐

3. Has the applicant ever surrendered (for cause) or had a state professional license or controlled substance registration revoked, suspended, denied, restricted, or placed on probation, or is any such action pending? YES NO
-
- ☐
- ☒

Date(s) of incident MM-DD-YYYY: ☐-☐-☐

4. If the applicant is a corporation (other than a corporation whose stock is owned and traded by the public), association, partnership, or pharmacy, has any officer, partner, stockholder, or proprietor been convicted of a crime in connection with controlled substance(s) under state or federal law, or ever surrendered, for cause, or had a federal controlled substance registration revoked, suspended, denied, restricted, or placed on probation, or is any such action pending? YES NO
-
- ☐
- ☒

Date(s) of incident MM-DD-YYYY: ☐-☐-☐

Note: If question 4 does not apply to you, be sure to mark 'NO'. It will slow down processing of your application if you leave it blank.

EXPLANATION OF "YES" ANSWERS

Liability question # _____

Location(s) of incident: _____

Applicants who have answered "YES" to any of the four questions above must provide a statement to explain each "YES" answer.

Nature of incident: _____

Use this space or attach a separate sheet and return with application

Disposition of incident: _____

SECTION 6 EXEMPTION FROM APPLICATION FEE

- ☒
- Check this box if the applicant is a federal, state, or local government official or institution. Does not apply to contractor-operated institutions.

Business or Facility Name of Fee Exempt Institution. Be sure to enter the address of this exempt institution in Section 1.

NDCS - PHARMACY

The undersigned hereby certifies that the applicant named hereon is a federal, state or local government official or institution, and is exempt from payment of the application fee.

FEE EXEMPT CERTIFIER

Signature of certifying official (other than applicant)

Date 4/15/11

Provide the name and phone number of the certifying official

Robert P. Houston

Print or type name and title of certifying official

402-479-5710

Telephone No. (required for verification)

SECTION 7**METHOD OF PAYMENT**

Check one form of payment only

- ☒
- Check Make check payable to: Drug Enforcement Administration See page 4 of instructions for important information.

- ☐
- American Express
- ☐
- Discover
- ☐
- Master Card
- ☐
- Visa

Credit Card Number

Expiration Date

Sign if paying by credit card

Signature of Card Holder

Printed Name of Card Holder

Mail this form with payment to:

U.S. Department of Justice
Drug Enforcement Administration
P.O. Box 28083
Washington, DC 20038-8083**FEE IS NON-REFUNDABLE****SECTION 8****APPLICANT'S SIGNATURE**

Sign in ink

I certify that the foregoing information furnished on this application is true and correct.

Signature of applicant (sign in ink)

Steve L. Vrosovich

Print or type name and title of applicant

Date 4/15/11

WARNING: Section 843(a)(4)(A) of Title 21, United States Code states that any person who knowingly or intentionally furnishes false or fraudulent information in the application is subject to imprisonment for not more than four years, a fine of not more than \$30,000, or both

SECTION 1. APPLICANT IDENTIFICATION - Information must be typed or printed in the blocks provided to help reduce data entry errors. A physical address is required in address line 1; a post office box or continuation of address may be entered in address line 2. Fee exempt applicant must list the address of the fee exempt institution. The email address, point of contact, national provider id, and date of birth are new data items that are in the process of OMB approval and will soon be mandatory. They are requested in order to facilitate communication or as required by inter-agency data sharing requirements. Applicant must enter a valid social security number (SSN), or a tax identification number (TIN) if applying as a business entity.

Debt collection information is mandatory pursuant to the Debt Collection Improvement Act of 1996.

SECTION 2. BUSINESS ACTIVITY - Indicate only one. Each type of business activity requires a separate application. You are required to register as a "manufacturer" if you manufacture a controlled substance or List 1 chemical and then distribute it.

SECTION 3A. SCHEDULES - Applicant should check all schedules to be handled. However, applicant must still comply with state requirements; federal registration does not overrule state restrictions. Check the order form box only if you intend to purchase or to transfer schedule 1 and 2 controlled substances. Order forms will be mailed to the registered address following issuance of a Certificate of Registration.

3B. MANUFACTURER ONLY - Mark the controlled substance schedule(s) handled in each manufacturing stage listed.

3C. SCHEDULE CODES - Report all drug codes as required for your business activity. Analytical lab is not required to list drug codes. Researcher of schedule 2-5 need only report schedule 2 drug codes that will be manufactured or imported as part of the research activity. Researcher of schedule 1 must report drug codes. Distributor or reverse distributor must list all schedule 1, and/or 2012 drug codes. Importer or exporter must check all schedule codes handled. Manufacturer must report all schedule 1 and 2 drug codes, and check all codes that are manufactured in bulk.

SECTION 4. STATE LICENSE(S) - Federal registration by DEA is based upon the applicant's compliance with applicable state and local laws. Applicant should contact the local state licensing authority prior to completing this application. If your state requires a license, provide that number on this application.

SECTION 5. LIABILITY - Applicant must answer all four questions for the application to be accepted for processing. If you answer "Yes" to a question, provide an explanation in the space provided. If you answer "Yes" to several of the questions, then you must provide a separate explanation describing the location, nature, and result of incident for each "Yes" answer. If additional space is required, you may attach a separate page.

SECTION 6. EXEMPTION - Exemption from payment of application fee is limited to federal, state or local government official or institution. The applicant's superior agency officer must certify exempt status. The signature, authority title, and telephone number of the certifying official (other than the applicant) must be provided. The address of the fee exempt institution must appear in Section 1.

SECTION 7. METHOD OF PAYMENT - Indicate the desired method of payment. Make checks payable to "Drug Enforcement Administration." Third-party checks, checks drawn on foreign banks will not be accepted. **FEES ARE NON-REFUNDABLE.**

SECTION 8. APPLICANT'S SIGNATURE - Applicant **MUST** sign in this section or application will be returned. Card holder signature in section 7 does not fulfill this requirement.

ATTACHMENTS: Researcher must attach 3 copies of protocol, including curriculum vitae, to conduct research with schedule 1 controlled substances. For clinical investigations, researcher must first submit to FDA a "Notice of Claimed Investigational Exemption for New Drug (IND)." See DEA web site or CFR 1301.18 for details.

Notice to Registrants Making Payment by Check

Authorization to Convert Your Check - If you send us a check to make your payment, your check will be converted into an electronic fund transfer. "Electronic fund transfer" is a term used to refer to the process in which we electronically instruct your financial institution to transfer funds from your account to our account, rather than processing your check. By sending your completed, signed check to us, you authorize us to copy your check and to use the account information from your check to make an electronic fund transfer from your account for the same amount as the check. If the electronic fund transfer cannot be processed for technical reasons, you authorize us to process the copy of your check.

Sufficient Funds - The electronic funds transfer from your account will usually occur within 24 hours, which is faster than a check is normally processed. Therefore, make sure there are sufficient funds available in your checking account when you send us your check. If the electronic funds transfer cannot be completed because of insufficient funds, we may try to make the transfer up to more two times.

Transaction Information - The electronic fund transfer from your account will be on the account statement you receive from your financial institution. However, the transfer may appear in a different place on your statement than the place where your checks normally appear. For example, it may appear under "other withdrawals" or "other transactions." You will not receive your original check back from your financial institution. For security reasons, we will destroy your original check, but we will keep a copy of the check for record-keeping purposes.

Your Rights - You should contact your financial institution immediately if you believe that the electronic fund transfer reported on your account statement was not properly authorized or is otherwise incorrect. Consumers have protections under Federal law called the Electronic Fund Transfer Act for an unauthorized or incorrect electronic fund transfer.

ADDITIONAL INFORMATION

No registration will be issued unless a completed application form has been received (21 CFR 1301.13).

In accordance with the Paperwork Reduction Act of 1995, no person is required to respond to a collection of information unless it displays a valid OMB control number. The OMB number for this collection is 1117-0012. Public reporting burden for this collection of information is estimated to average 15 minutes per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the information.

The Debt Collection Improvements Act of 1996 (PL 104-134) requires that you furnish your Taxpayer Identification Number and/or Social Security Number on this application. This number is required for debt collection procedures if your fee is not collectible.

PRIVACY ACT INFORMATION

AUTHORITY: Section 302 and 303 of the Controlled Substances Act of 1970 (PL 91-513) and Debt Collection Improvements Act of 1996 (PL 104-134) for SSN and/or TIN.

PURPOSE: To obtain information required to register applicants pursuant to the Controlled Substances Act of 1970.

ROUTINE USES: The Controlled Substances Act registration system produces special reports as required for statistical analytical purposes.

Disclosures of information from this system are made to the following:

- A. Other federal law enforcement and regulatory agencies for law enforcement and regulatory purposes
- B. State and local law enforcement and regulatory agencies for law enforcement and regulatory purposes
- C. Persons registered under the Controlled Substances Act (PL 91-513) for the purpose of verifying registration

EFFECT: Failure to complete form will preclude processing of the application.

INTERNET:
www.deadiversion.usdoj.gov

TELEPHONE:
HQ Call Center (800)882-9539

WRITTEN INQUIRIES:
DEA
P.O. Box 28083
Washington, D.C. 20035-8083

Green, George

From: Werner, Patrick on behalf of Urosevich, Steve
Sent: Tuesday, May 17, 2011 10:23 AM
To: Werner, Patrick
Subject: FW: Revised application for DEA import registration

From: Urosevich, Steve
Sent: Thursday, May 12, 2011 10:04 AM
To: michele.d.herron@usdoj.gov
Cc: Houston, Bob
Subject: Revised application for DEA import registration

Michele,

Please allow this e-mail to serve as clarification that Nebraska Department of Correctional Services only intends to import schedule 3 drug Thiopental, code#2329, thank you for your assistance in this important matter. We understand that this application will now be processed through the local DEA Office which is normally a seven (7) to ten (10) day process.

Steve L. Urosevich
Chief Operating Officer, Health Services
Nebraska Department of Corrections
steve.urosevich@nebraska.gov
Ofc. 402-479-5630
Cell. 402-214-1156
Fax. 402-479-5679

6/8/2011

Phone call with Judy Williams on May 17, 2011

I had spoken earlier in the day with Tom Cox, Supervisor of the Des Moines DEA Office. He had returned my call when it was thought his office would process our 225 application as an importer. I explained the fact that Judy Williams was to make a site inspection with Scott Collier on May 25th, however, with the Form 236 15day notification period, the drug would probably not arrive in the US until Jun 13th at the earliest. I asked if thru interagency cooperation his office could make the inspection visit earlier since it is only 3 hours from Lincoln. He said that was possible but Scott Collier in St Louis, his boss would need to agree also Judy Williams would need to agree. He suggested I call Judy Williams. I did call and shared with her my conversation with Tom Cox, she said that she is the one responsible and we need to stick with the 25th but she would call Scott Collier.

A handwritten signature in black ink, appearing to read "Judy Williams", with a long horizontal flourish extending to the right.

4/17/11

(2)

Division
control.

Betty Venev / Steve U

Betty is DEA 202-307-7181
needs AN#

brother did not obtain import registration

AN5903453. this actually hosp/clinic

unit chief on phone, she wants to discuss
with him.

Betty will go stand @ chief's desk. regis is
not

- same as sodium Vinorelbine

- clinic registration ≠ import need import
registration or researcher registration

- doesn't know if we have contact in
an import registration

- will not take AN#

- if we know one of a more they can import
for us.

- possible for us to get registration,
doesn't know how long.

(2)

- go on line fill out regis as importer
- come, go on web. Departmental
- not a hurry fill out app as importer.
- we're web. D&A web will contact us. assign to investigator. they would come out. where stored, etc.
- contact them now. D&A, 236 or registration #. Business activity, lab analytical research importer/exporter.

Q

- fill out app - consult D&A web.

• everything is OK. it has happened before that 236 form not filled out, because they had done this. not necessary to write letter.

(3)

• ~~DELETED~~

(515) 284-4209 J.A. - Des Moines

(913) 825-4200 KC

Deversion Specialist

They will assist in copy with res
They will assign a person to follow

~~DELETED~~ 225 ~~DELETED~~ new applicat as
updater

Judy Williams D&A
(913) 951-4108

- no emails
- has known for a week or two
- didn't try to come to line
- has product now.
- no pending execution
- one-time
- Scott Collier in St Louis boss
- if not plan on input in future
- collect the drugs from us
have it destroyed
- admonition
- response.

GEORGE GREEN

NOTES

041211

041211 Steve Urosevich and I spoke to Betty Veney with Diversion Control of DEA approximately 1000. She is the Diversion Specialist for DEA in Washington DC. She advised that our broker did not obtain an import export registration. In order to import drug an entity must be engaged in one of the business activities on their form 225. (There are several, Analytical Lab, Researcher Schedule I, Researcher Schedule II – V, Canine Handler, Distributer, Exporter, Importer, Reverse Distributer, Manufacturer, Manufacturer BULK.) We should be listed as an importer. The registration held at NSP is of a hospital clinic, which is not the proper activity for importing drugs.

In order to get the correct permission we need to complete the form 225 as an importer exporter. She gave me the numbers for the DEA in Kansas City and Des Moines. It is possible for us to get the correct registration, and this has happened in the past. She said that that it was not that big of a deal that the form 225 was not filled out. She said that it was not necessary for us to write a letter stating that we would not use the medication until the matter was resolved, nor was it necessary for us to write a letter to DEA.

When we contact DEA they will assign us a Diversion Specialist to assist us to comply with the Rules, who will also follow us through the process.

At approximately 2:30 I spoke to Judy Williams DEA. Steve Urosevich was present.

- She said that we should not exchange emails.
- DEA has known for a week or two that we possessed drugs.
- They didn't try to come to Lincoln.
- She asked if we had the product now. I said that we did.
- She asked if there was pending execution. I said there was not.
- She remembered that I spoke to her on the phone last summer.
- She recalled that I was low key and reasonable.
- I told her that this was a one time importation.
- She said that she needed to talk to her supervisor in St. Louis.
- If we do not plan on importing drugs in the future, they would come and collect the drugs from us, she thinks.
- They will be destroyed.
- DEA could issue us an admonition. We could respond.

Bob Houston asked me to call Betty Veni and tell her how different the conversation was between the first conversation and the second. I left her a voice mail.

At 335 Judy Williams called me back. She wanted to know the sequence of events leading to our telephone call to DEA. If this was high on her radar, she'd be on her way to Lincoln.

GEORGE GREEN
NOTES

Page two notes.

This is ~~not~~ high on her radar scheme. She is not asking us for \$. There will be no fine. This will not be fixed ~~this~~ week.

GEORGE GREEN
NOTES 041111

- DCS was not designated as the importer under the CSA by the broker who handled the transaction.
- The broker was handling a subsequent transaction and learned that a form 236 was required. They contacted DCS and informed us that they were filing a form 236. We signed the form 236 on April 1, 2011.
- We have been contacted by DEA, and we contacted her back today. We called twice and left call back numbers.

236 identifies as as importer.

4/12 @

Jerry Wms 3:38pm
if this were high on radar (9/3) 951-41108
she'd be a car on way to Amer.


not preclude importer registration upch.

this is not high on her radar. paperwork
not appropriate.

no \$. not fixed this wk.

Rx controlled substances? if not no DEA
but FDA needed.

4/12 4:03



4/11/11

(B)

Steve U. conf call

tele call to Megan Cooley

Sharon Lindgren

- form #236 DEA request? No.

They were handling an import for S. Dak. Then they found it out was required. Technically submitted 15 days before it arrived.

for compliance's sake submitted

- 5 copies signed. 1st one sent with shipment.

- customs & DEA get forms, since we have DEA # not likely they will take it away

- category of activity is hosp/clinic does that designation allow us to import that medication.

- Phil Cooley is ~~not~~ importer. for this ship they are importer. they paid bond. they are the importer of record.

- for S. Dakota they were not the importer - single entry bond.

- you only have

②

• hospira analysis of code to
Dogs wh.

[REDACTED]

[REDACTED]

0

0

Green, George

From: Megan Cooley [megan@ppioma.com]
Sent: Wednesday, March 30, 2011 4:20 PM
To: Green, George
Subject: Import of Sodium Thiopental
Attachments: SKMBT_C45111033014280.pdf

Good Afternoon,

Per our conversation, at the time of importation for the above listed commodity both FDA and CBP were contacted to find out if there were any special provisions as to what would be needed to release this shipment. At the time of importation, we as a company, had never handled the importation of this commodity prior to this shipment. Based on the feedback we were given from both government agencies the DEA Form 236 was not given as a requirement for this import, therefore one was never submitted on behalf of the State of NE Dept. of Corrections.

In addition to the DEA forms required, there was question as to whether an Application for Import Permit of Controlled Substance (DEA Form 357) was completed and the answer to this is no. I have attached a chart that can be found on DEA's website showing that since this is a Schedule III non-narcotic controlled substance this form was not required.

Should you have any further questions, please feel free to contact me.

Best Regards,

Megan Cooley
Phil Patterson, Inc.
402-344-4636

*forwarded
to SKB
3/30*

3/30/2011



External links included in this website should not be construed as an official endorsement of the views contained therein.

Any FAX transmittals should be directed to 202-307-7503.

Please feel free to contact us at the above numbers whenever you have any ques

Controlled Substances Import-Export Form Guide

Controlled Substances Act Schedule	DEA-161	DEA-357	C
			Impor
Schedule I	X	X	
Schedule II	X	X	
Schedule III Narcotic	X	X	
Schedule III Nonnarcotic (except for delta-9-THC which requires a permit)			X
Schedule IV Narcotic	X	X	
Schedule IV Nonnarcotic			X
Schedule V Narcotic		X	
Schedule V Nonnarcotic			X

DEA-161 Application for Export Permit

DEA-357 Application for Import Permit


DEA-236 Declaration

[Back to Top](#)

[Home](#) | [Registration](#) | [Reporting](#) | [Info & Legal Resources](#) | [Inside Diversion Control](#) | [Privacy Statement](#)

Green, George

From: Megan Cooley [megan@ppioma.com]
Sent: Friday, April 01, 2011 1:17 PM
To: Werner, Patrick
Cc: Green, George
Subject: RE: DEA 236



Thank you! This will be sent to DEA today.

Megan

From: Werner, Patrick [mailto:patrick.werner@nebraska.gov]
Sent: Friday, April 01, 2011 1:12 PM
To: Megan Cooley
Cc: Green, George
Subject: DEA 236

Hello Megan,

Per request, please find attached the signed documents.

Have a great day,

Patrick

From: DCS BLDG 1 [mailto:dcscopiers@nebraska.gov]
Sent: Friday, April 01, 2011 12:12 PM
To: Werner, Patrick
Subject: DCS Attached Image

4/6/2011

CONTROLLED SUBSTANCES IMPORT / EXPORT DECLARATION

(Read Instructions on reverse before completing)

OMB APPROVAL
No. 1117 - 0089

See reverse for Privacy Act

1. CHECK ONE <input checked="" type="checkbox"/> IMPORT DECLARATION <input type="checkbox"/> EXPORT DECLARATION	Nonnarcotic Substances in Schedules III, IV, V	U.S. CUSTOMS CERTIFICATION
	Nonnarcotic Substances in Schedules III, and IV and all substances in Schedule V	
IMPORTER/EXPORTER (Name and Address) STATE OF NEBRASKA, DEPT. OF CORRECTIONS PO BOX 94661 LINCOLN, NE 68509		Date of Departure / Arrival
BROKER OR FORWARDING AGENT, IF USED (Name and Address) PHIL PATTERSON, INC. 1209 HARNEY ST. OMAHA, NE 68102		Name of Carrier / Vessel
DEA REGISTRATION NO. AN 5903453		Date of Certification
		Signature of Customs Official

2. CONTROLLED SUBSTANCES TO BE IMPORTED OR EXPORTED

2a. NAME AND QUANTITY OF DRUG or PREPARATION (Enter names as shown on labels; numbers and sizes of packages; strength of tablets, capsules, etc., CSA Drug Code and NDC Number)	2b. CONTROLLED SUBSTANCE CONTENT OF DRUG OR PREPARATION expressed as acid, base or alkaloid. (Enter names of controlled substances contained in the drug; compound, or preparation)	2c. DATE IMPORTED/EXPORTED AND ACTUAL QUANTITY (Completed by registrant at time of transaction)
THIOPENTONE INJECTION IP 1 GM "THIOSOL SODIUM" QTY 500 - 20X25 VIALS DRUG LICENSE NUMBER 21BZ-7/103/2135	THIOSOL SODIUM (THIOPENTONE INJECTION)	

3. <input checked="" type="checkbox"/> FOREIGN <input type="checkbox"/> DOMESTIC PORT OF EXPORTATION (last U.S. Customs Port) AND APPROX. DEPARTURE DATE MUMBAI (BOMBAY) INDIA 12/09/10	<input type="checkbox"/> FOREIGN <input checked="" type="checkbox"/> DOMESTIC PORT OF IMPORTATION (first U.S. Customs Port) AND APPROX. ARRIVAL DATE NEWARK, NJ 12/12/10
--	---

4. MODE OF TRANSPORT; NAME OF VESSEL / CARRIER (if known) AIR - CONTINENTAL AIRLINES FLT CO049	NAME OF ALL INTERMEDIATE CARRIERS CEVA LOGISTICS - TRUCKER FROM NEWARK
---	---

5. NAME AND ADDRESS OF FOREIGN CONSIGNEE/CONSIGNOR
NEON LABORATORIES LTD
143 DAMJI SHAMJI INDUSTRIAL COMPLEX
CHAKALA M.I.D.C., MUMBAI MAHARASHTRA 400093, INDIA


I hereby certify that the above named substance(s) to be ☒ Imported, ☐ Exported, are intended for ☐ Legitimate medical need, ☐ Scientific research, ☒ Other (If intended for reexport beyond the country of destination described in block 5 above, attach documentation per Title 21, CFR 1312.27.)
If used as "Export Declaration", attach documentation that importation is not contrary to the laws or regulations of the country of destination.

SIGNATURE OF AUTHORIZED INDIVIDUAL OF IMPORTER/EXPORTER, BROKER OR FORWARDING AGENT	DATE	NAME OF FIRM AND TELEPHONE NUMBER
---	------	-----------------------------------

Shilpa...
Dec 14, 2010

Dec 14, 2010

STATE OF NEBRASKA, DEPT. OF CORRECTIONS
(402) 479-5630

U. S. Department of Justice / Drug Enforcement Administration CONTROLLED SUBSTANCES IMPORT / EXPORT DECLARATION <i>(Read Instructions on reverse before completing)</i>		OMB APPROVAL No. 1117 - 0009
		See reverse for Privacy Act
1. <input checked="" type="checkbox"/> IMPORT DECLARATION Nonnarcotic Substances in Schedules III, IV, V <input type="checkbox"/> EXPORT DECLARATION Nonnarcotic Substances in Schedules III, and IV and all substances in Schedule V		U.S. CUSTOMS CERTIFICATION Date of Departure / Arrival
IMPORTER/EXPORTER (Name and Address) STATE OF NEBRASKA, DEPT. OF CORRECTIONS PO BOX 94661 LINCOLN, NE 68509 DEA REGISTRATION NO. AN 5903453		BROKER OR FORWARDING AGENT, IF USED (Name and Address) PHIL PATTERSON, INC. 1209 HARNEY ST. OMAHA, NE 68102
		Name of Carrier / Vessel Date of Certification Signature of Customs Official
2. CONTROLLED SUBSTANCES TO BE IMPORTED OR EXPORTED		
2a. NAME AND QUANTITY OF DRUG or PREPARATION <i>(Enter names as shown on labels; numbers and sizes of packages; strength of tablets, capsules, etc., CSA Drug Code and NDC Number)</i>	2b. CONTROLLED SUBSTANCE CONTENT OF DRUG OR PREPARATION expressed as acid, base or alkaloid. <i>(Enter names of controlled substances contained in the drug; compound, or preparation)</i>	2c. DATE IMPORTED/EXPORTED AND ACTUAL QUANTITY <i>(Completed by registrant at time of transaction)</i>
THIOPENTONE INJECTION IP 1 GM "THIOSOL SODIUM" QTY 500 - 20X25 VIALS DRUG LICENSE NUMBER 21BZ-7/103/2135	THIOSOL SODIUM (THIOPENTONE INJECTION)	
3. <input checked="" type="checkbox"/> FOREIGN <input type="checkbox"/> DOMESTIC PORT OF EXPORTATION (last U.S. Customs Port) AND APPROX. DEPARTURE DATE MUMBAI (BOMBAY) INDIA 12/09/10		<input type="checkbox"/> FOREIGN <input checked="" type="checkbox"/> DOMESTIC PORT OF IMPORTATION (first U.S. Customs Port) AND APPROX. ARRIVAL DATE NEWARK, NJ 12/12/10
4. MODE OF TRANSPORT; NAME OF VESSEL / CARRIER (if known) AIR - CONTINENTAL AIRLINES FLT C0049		NAME OF ALL INTERMEDIATE CARRIERS CEVA LOGISTICS - TRUCKER FROM NEWARK
5. NAME AND ADDRESS OF FOREIGN CONSIGNEE/CONSIGNOR NEON LABORATORIES LTD 143 DAMJI SHAMJI INDUSTRIAL COMPLEX CHAKALA M.I.D.C., MUMBAI MAHARASHTRA 400093, INDIA		
I hereby certify that the above named substance(s) to be <input checked="" type="checkbox"/> Imported, <input type="checkbox"/> Exported, are intended for <input type="checkbox"/> Legitimate medical need, <input type="checkbox"/> Scientific research, <input checked="" type="checkbox"/> Other (If intended for reexport beyond the country of destination described in block 5 above, attach documentation per Title 21, CFR 1312.27.) If used as "Export Declaration", attach documentation that importation is not contrary to the laws or regulations of the country of destination.		
SIGNATURE OF AUTHORIZED INDIVIDUAL OF IMPORTER/EXPORTER, BROKER OR FORWARDING AGENT 		NAME OF FIRM AND TELEPHONE NUMBER STATE OF NEBRASKA, DEPT. OF CORRECTIONS (402) 479-5630
DATE Dec 14, 2010		
DEA Form - 236 (Apr. 1988) Previous edition dated 4/80 is OBSOLETE. COPY 2		

CONTROLLED SUBSTANCES IMPORT / EXPORT DECLARATION

(Read Instructions on reverse before completing)

OMB APPROVAL
No. 1117 - 0009

See reverse for Privacy Act

1. CHECK ONE
- ☒ **IMPORT DECLARATION** Nonnarcotic Substances in Schedules III, IV, V
- ☐ **EXPORT DECLARATION** Nonnarcotic Substances in Schedules III, and IV and all substances in Schedule V

IMPORTER/EXPORTER (Name and Address)
STATE OF NEBRASKA, DEPT. OF
CORRECTIONS
PO BOX 94661
LINCOLN, NE 68509

BROKER OR FORWARDING AGENT, IF USED
(Name and Address)
PHIL PATTERSON, INC.
1209 HARNEY ST.
OMAHA, NE 68102

U.S. CUSTOMS
CERTIFICATION

Date of Départure / Arrival

Name of Carrier / Vessel

Date of Certification

Signature of Customs Official

DEA REGISTRATION NO. AN 5903453

2. CONTROLLED SUBSTANCES TO BE IMPORTED OR EXPORTED

2a. NAME AND QUANTITY OF DRUG or PREPARATION
(Enter names as shown on labels; numbers and sizes
of packages; strength of tablets, capsules, etc.,
CSA Drug Code and NDG Number)

THIOPENTONE INJECTION IP 1 GM
"THIOSOL SODIUM"

QTY 500 - 20X25 VIALS

DRUG LICENSE NUMBER 21BZ-7/103/2135

2b. CONTROLLED SUBSTANCE CONTENT OF DRUG
OR PREPARATION expressed as acid, base or
alkaloid. (Enter names of controlled substances
contained in the drug; compound, or preparation)

THIOSOL SODIUM (THIOPENTONE
INJECTION)

2c. DATE IMPORTED/EXPORTED
AND ACTUAL QUANTITY
(Completed by registrant at time
of transaction)

3. ☒ FOREIGN ☐ DOMESTIC PORT OF EXPORTATION (last U.S.
Customs Port) AND APPROX. DEPARTURE DATE
MUMBAI (BOMBAY) INDIA 12/09/10

☐ FOREIGN ☒ DOMESTIC PORT OF IMPORTATION (first U.S.
Customs Port) AND APPROX. ARRIVAL DATE
NEWARK, NJ 12/12/10

4. MODE OF TRANSPORT; NAME OF VESSEL / CARRIER (if known)
AIR - CONTINENTAL AIRLINES FLT CO049

NAME OF ALL INTERMEDIATE CARRIERS
CEVA LOGISTICS - TRUCKER FROM NEWARK

5. NAME AND ADDRESS OF FOREIGN CONSIGNEE/CONSIGNOR

NEON LABORATORIES LTD
143 DAMJI SHAMJI INDUSTRIAL COMPLEX
CHAKALA M.I.D.C., MUMBAI MAHARASHTRA 400093, INDIA

I hereby certify that the above named substance(s) to be ☒ Imported, ☐ Exported, are intended for ☐ Legitimate medical need, ☐ Scientific research,
☒ Other (If intended for reexport beyond the country of destination described in block 5 above, attach documentation per Title 21, CFR 1312.27.)

If used as "Export Declaration", attach documentation that importation is not contrary to the laws or regulations of the country of destination.

SIGNATURE OF AUTHORIZED INDIVIDUAL OF IMPORTER/
EXPORTER, BROKER OR FORWARDING AGENT


DATE


Dec 14, 2010

NAME OF FIRM AND TELEPHONE NUMBER

STATE OF NEBRASKA, DEPT. OF CORRECTIONS

(402) 479-5630

U. S. Department of Justice / Drug Enforcement Administration CONTROLLED SUBSTANCES IMPORT / EXPORT DECLARATION (Read Instructions on reverse before completing)		OMB APPROVAL No. 1117 - 0009
		See reverse for Privacy Act
1. CHECK ONE <input checked="" type="checkbox"/> IMPORT DECLARATION Nonnarcotic Substances in Schedules III, IV, V <input type="checkbox"/> EXPORT DECLARATION Nonnarcotic Substances in Schedules III, and IV and all substances in Schedule V		U.S. CUSTOMS CERTIFICATION Date of Departure / Arrival Name of Carrier / Vessel Date of Certification Signature of Customs Official
IMPORTER/EXPORTER (Name and Address) STATE OF NEBRASKA, DEPT. OF CORRECTIONS PO BOX 94661 LINCOLN, NE 68509 DEA REGISTRATION NO. AN 5903453		BROKER OR FORWARDING AGENT, IF USED (Name and Address) PHIL PATTERSON, INC. 1209 HARNEY ST. OMAHA, NE 68102
2. CONTROLLED SUBSTANCES TO BE IMPORTED OR EXPORTED		
2a. NAME AND QUANTITY OF DRUG or PREPARATION (Enter names as shown on labels; numbers and sizes of packages; strength of tablets, capsules, etc., CSA Drug Code and NDC Number)	2b. CONTROLLED SUBSTANCE CONTENT OF DRUG OR PREPARATION expressed as acid, base or alkaloid. (Enter names of controlled substances contained in the drug; compound, or preparation)	2c. DATE IMPORTED/EXPORTED AND ACTUAL QUANTITY (Completed by registrant at time of transaction)
THIOPENTONE INJECTION IP 1 GM "THIOSOL SODIUM" QTY 500 - 20X25 VIALS DRUG LICENSE NUMBER 21BZ-7/103/2135	THIOSOL SODIUM (THIOPENTONE INJECTION)	
3. <input checked="" type="checkbox"/> FOREIGN <input type="checkbox"/> DOMESTIC PORT OF EXPORTATION (last U.S. Customs Port) AND APPROX. DEPARTURE DATE MUMBAI (BOMBAY) INDIA 12/09/10		<input type="checkbox"/> FOREIGN <input checked="" type="checkbox"/> DOMESTIC PORT OF IMPORTATION (first U.S. Customs Port) AND APPROX. ARRIVAL DATE NEWARK, NJ 12/12/10
4. MODE OF TRANSPORT; NAME OF VESSEL / CARRIER (if known) AIR - CONTINENTAL AIRLINES FLT C0049		NAME OF ALL INTERMEDIATE CARRIERS CEVA LOGISTICS - TRUCKER FROM NEWARK
5. NAME AND ADDRESS OF FOREIGN CONSIGNEE/CONSIGNOR NEON LABORATORIES LTD 143 DAMJI SHAMJI INDUSTRIAL COMPLEX CHAKALA M.I.D.C., MUMBAI MAHARASHTRA 400093, INDIA		
I hereby certify that the above named substance(s) to be <input checked="" type="checkbox"/> Imported, <input type="checkbox"/> Exported, are intended for <input type="checkbox"/> Legitimate medical need, <input type="checkbox"/> Scientific research, <input checked="" type="checkbox"/> Other (If intended for reexport beyond the country of destination described in block 5 above, attach documentation per Title 21, CFR 1312.27.) If used as "Export Declaration", attach documentation that importation is not contrary to the laws or regulations of the country of destination.		
SIGNATURE OF AUTHORIZED INDIVIDUAL OF IMPORTER/EXPORTER, BROKER OR FORWARDING AGENT 	DATE Dec 14, 2010	NAME OF FIRM AND TELEPHONE NUMBER STATE OF NEBRASKA, DEPT. OF CORRECTIONS (402) 479-5630

U. S. Department of Justice / Drug Enforcement Administration CONTROLLED SUBSTANCES IMPORT / EXPORT DECLARATION <i>(Read Instructions on reverse before completing)</i>		OMB APPROVAL No. 1117 - 0009
		See reverse for Privacy Act
1. CHECK ONE <input checked="" type="checkbox"/> IMPORT DECLARATION Nonnarcotic Substances in Schedules III, IV, V <input type="checkbox"/> EXPORT DECLARATION Nonnarcotic Substances in Schedules III, and IV and all substances in Schedule V		U.S. CUSTOMS CERTIFICATION Date of Departure / Arrival Name of Carrier / Vessel Date of Certification Signature of Customs Official
IMPORTER/EXPORTER (Name and Address) STATE OF NEBRASKA, DEPT. OF CORRECTIONS PO BOX 94661 LINCOLN, NE 68509 DEA REGISTRATION NO. AN 5903453		BROKER OR FORWARDING AGENT, IF USED (Name and Address) PHIL PATTERSON, INC. 1209 HARNEY ST. OMAHA, NE 68102
2. CONTROLLED SUBSTANCES TO BE IMPORTED OR EXPORTED		
2a. NAME AND QUANTITY OF DRUG or PREPARATION <i>(Enter names as shown on labels; numbers and sizes of packages; strength of tablets, capsules, etc., CSA Drug Code and NDC Number)</i> THIOFENTONE INJECTION IP 1 GM "THIOSOL SODIUM" QTY 500 - 20X25 VIALS DRUG LICENSE NUMBER 21BZ-7/103/2135	2b. CONTROLLED SUBSTANCE CONTENT OF DRUG OR PREPARATION expressed as acid, base or alkaloid. <i>(Enter names of controlled substances contained in the drug; compound, or preparation)</i> THIOSOL SODIUM (THIOFENTONE INJECTION)	2c. DATE IMPORTED/EXPORTED AND ACTUAL QUANTITY <i>(Completed by registrant at time of transaction)</i>
3. <input checked="" type="checkbox"/> FOREIGN <input type="checkbox"/> DOMESTIC PORT OF EXPORTATION (last U.S. Customs Port) AND APPROX. DEPARTURE DATE MUMBAI (BOMBAY) INDIA 12/09/10		<input type="checkbox"/> FOREIGN <input checked="" type="checkbox"/> DOMESTIC PORT OF IMPORTATION (first U.S. Customs Port) AND APPROX. ARRIVAL DATE NEWARK, NJ 12/12/10
4. MODE OF TRANSPORT; NAME OF VESSEL / CARRIER (if known) AIR - CONTINENTAL AIRLINES FLT CO049		NAME OF ALL INTERMEDIATE CARRIERS CEVA LOGISTICS - TRUCKER FROM NEWARK
5. NAME AND ADDRESS OF FOREIGN CONSIGNEE/CONSIGNOR NEON LABORATORIES LTD 143 DAMJI SHAMJI INDUSTRIAL COMPLEX CHAKALA M.I.D.C., MUMBAI MAHARASHTRA 400093, INDIA		
I hereby certify that the above named substance(s) to be <input checked="" type="checkbox"/> Imported, <input type="checkbox"/> Exported, are intended for <input type="checkbox"/> Legitimate medical need, <input type="checkbox"/> Scientific research, <input checked="" type="checkbox"/> Other (If intended for reexport beyond the country of destination described in block 5 above, attach documentation per Title 21, CFR 1312.27.) If used as "Export Declaration", attach documentation that importation is not contrary to the laws or regulations of the country of destination.		
SIGNATURE OF AUTHORIZED INDIVIDUAL OF IMPORTER/EXPORTER, BROKER OR FORWARDING AGENT 		NAME OF FIRM AND TELEPHONE NUMBER STATE OF NEBRASKA, DEPT. OF CORRECTIONS (402) 479-5630
DATE Dec 14, 2010		
DEA Form - 236 (Apr. 1988) Previous edition dated 4/80 is OBSOLETE. COPY 5		

5/77

- Mrs McKersie referred me to KC office

- Judy Williams 913-825-4201

- Group Supervisor KCMO
913 - 825 - 4200

- need some lens & she will call me back a few days needs to kick it away

- question of first impression

Drug Enforcement Admin.

- Contact Ms. Dickenson (DEA)
O: 202-307-8617 F: 202-307-4643
- Section 2, 3, 4 of DEA Application
- Inga Hookstra has that - but gone for 2 weeks. Joyce will get info to Robin then Robin to use.
- Information that we need from Inga.

- Spoke with Ms. Dickenson and she stated they would fax over section 2, 3 & 4 of the application, but it would be blank because they are not allowed to send out in any way completed copies of applications.